COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third programme of Union action in the field of health (2018)
Date: 2020-11-06
Institutions: Directorate-General for Health and Food Safety, European Commission
Subjects: EU programme, disease prevention, health care, health care system, implementation of the budget, innovation, programme budgeting, public health

EN 

  EN 

   EUROPEAN COMMISSION  Brussels, 6.11.2020  SWD(2020) 256 final  COMMISSION STAFF WORKING DOCUMENT Accompanying the document Report from the Commission to the European Parliament and the Council Implementation of the third programme of Union action in the field of health (2018)  {COM(2020) 691 final}  
 
 
Table of Contents 

Introduction ............................................................................................................................................................... 5 

JOINT ACTIONS ..................................................................................................................................................... 6 

1. 

Joint action on reducing alcohol-related harm (RARHA) ................................................................................ 6 

2. 

Joint action on nutrition and physical activity (JANPA) .................................................................................. 7 

3. 

Joint action to support the eHealth network (JAseHN) .................................................................................... 9 

4.  Strengthening cooperation to operate pharmacovigilance in Europe (SCOPE).............................................. 10 

PROJECTS ............................................................................................................................................................. 13 

1.  Tobacco cessation guidelines for high-risk groups (TOB.g) .......................................................................... 13 

2.  Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community-
dwelling persons from EU countries (SUNFRAIL)................................................................................................ 14 

3.  Operational knowledge to improve the early diagnosis and treatment of HIV among vulnerable groups 
in Europe (Euro HIV EDAT) .................................................................................................................................. 15 

4.  Statistical  data  and  guidance  document  for  medicinal  product  pricing  and  for  the  use  of  external 
reference pricing (EURIPID) .................................................................................................................................. 18 

5.  BRidging  Information  and  Data  Generation  for  Evidence-based  Health  Policy  and  Research 
(BRIDGE Health) ................................................................................................................................................... 20 

6.  European  Expert  Paediatric  Oncology  Reference  Network  for  Diagnostics  and  Treatment  (ExPO-r-
Net) 21 

OPERATING GRANTS ......................................................................................................................................... 23 

1.  European cancer leagues cooperating for impact on cancer control ............................................................... 24 

2.  Smoke-free partnership coalition: smoking prevention in action ................................................................... 26 

3.  European network for smoking and tobacco prevention (ENSP) – united for a tobacco-free Europe ........... 28 

DIRECT GRANT AGREEMENTS WITH INTERNATIONAL ORGANISATIONS.......................................... 30 

1.  OECD health workforce: feasibility study for an international survey of health workers’ skills ................... 30 

2.  OECD - economic burden and health impact of antimicrobial resistance ...................................................... 31 

CALLS FOR TENDERS ........................................................................................................................................ 33 

1.  Further  development  and  implementation  of  the  ‘EU  compass  for  action  on  mental  health  and 
wellbeing’ ............................................................................................................................................................... 33 

2.  Study on cross-border cooperation: capitalising on existing initiatives for cooperation in cross-border 
regions (request for specific services No Chafea/2016/Health/22) ......................................................................... 35 

1 

 
 
3.  Provision of a market study on telemedicine (request for specific services Chafea/2016/Health/17) ............ 37 

HIGHLIGHTS OF CO-FUNDED ‘CROSS-CUTTING’ AND ‘OTHER’ ACTIONS .......................................... 39 

1.  Dissemination activities carried out in 2018 ..................................................................................... 39 

2.  Other actions ..................................................................................................................................... 40 

2.1. 

Sub-delegations to Eurostat, the statistical office of the European Union .................................... 40 

Background information ......................................................................................................................................... 40 

2.2.  What did the ERNs achieve in practice with the first year of SGA support? ............................... 42 

IMPLEMENTATION OF THE ANNUAL WORK PROGRAMME FOR 2018 ................................................... 45 

CALLS FOR PROPOSALS ..................................................................................................................................... 45 

Expert evaluators ...................................................................................................................................... 46 

Project grants ............................................................................................................................................ 47 

European reference networks (mono-beneficiary grants) ......................................................................... 50 

Operating grants ........................................................................................................................................ 51 

JOINT ACTIONS ..................................................................................................................................... 54 

DIRECT GRANT AGREEMENTS AND PRESIDENCY CONFERENCES ......................................... 55 

Other direct grants ..................................................................................................................................... 57 

Presidency conferences ............................................................................................................................. 57 

PRIZES – EU health award for NGOs ...................................................................................................... 58 

PROCUREMENTS (SERVICE CONTRACTS) ...................................................................................... 59 

OTHER ACTIONS ................................................................................................................................... 72 

DETAILED OVERVIEW OF THE REPORTING YEAR 2018 ........................................................................... 76 

Funding per thematic priority and financial instrument ............................................................................ 76 

2 

 
 
 
 
 
Introduction 

This  Commission  staff  working  document  (SWD)  accompanies  the  report  on  the  implementation  of  the 

third  health  programme  (‘the  programme’)  in  2018.  The  report  provides  an  overview  of  all  the  actions 

funded under the annual work programme for 2018 (2018 AWP). The Commission SWD showcases the 

key results achieved in 2018 by actions co-funded under the programme in previous years, divided up by 

financing  mechanism  (grants  and  service  contracts).  These  actions  fall  under  the  four  objectives  of  the 

second and third health programmes. 

The  SWD  also  provides  the  full  figures  and  statistics  of  the  programme’s  2018  operational  budget, 

including  the  lists  of  all  co-funded  initiatives  and  contracts  by  programme  objective,  type  of  action  and 

type of beneficiary organisation. 

Several actions co-funded under the second health programme came to an end in late 2017 and in 2018, 

and achieved important results that were taken up at national or EU level. Several examples are described 

in the document.  

More  information  about  these  actions  and  their  outputs  can  be  found in the  health  programme  database1 
managed by the Consumers, Health, Agriculture and Food Executive Agency (Chafea)2. 

1 The database covers actions co-funded under the health programmes from 2003 to 2020. 
2 http://ec.europa.eu/chafea/health/index.html  

3 

 
 
 
 
                                                      
JOINT ACTIONS 

Objective  1.  Promote  health,  prevent  diseases  and  foster  supportive  environments  for  healthy 
lifestyles 

1.  Joint action on reducing alcohol-related harm (RARHA)  

More  information  is  available  on  the  joint  action  (JA)  website3  and  in  Chafea’s  Health  Programme 
database4.  

Background information  

The RARHA JA was funded under the 2013 annual work programme to support EU countries in working 

on shared priorities in line with the EU alcohol strategy. 

The  JA  was  coordinated  by  Portugal,  specifically  the  Ministry  of  Health’s  department  for  combating 

addictions  and  dependent  behaviours  (Serviço  de  Intervenção  nos  Comportamentos  Aditivos  e  nas 

Dependências.  It  involved  32  associated  partners  and  29  collaborating  partners from  all  28  EU  Member 

States plus Iceland, Norway and Switzerland. The EU contribution was EUR 1 533 383. 

Brief description of activities  

The  RARHA  JA  contributed  to  capacity  building  in  alcohol  prevention  among  EU  countries  and  in  the 

wider public health community through three core activities: 

  work  package  (WP)  4  focused  on  strengthening  capacity  in  alcohol  survey  methodology  and 

providing a common instrument for monitoring progress in reducing alcohol-related harm;  

  WP5 worked to highlight the scientific basis and provide information on the practical implications 

of  drinking  guidelines  as  a  public  health  measure,  to  build  consensus  on  key  messages  about 

harmful drinking to the general public and health professionals;  

  WP6 focused on improving access to cost-efficient, transferable interventions that proved effective 

both in influencing attitudes or behaviour and in terms of cost.  

3 Joint action on  reducing alcohol-related harm: http://www.rarha.eu/Pages/default.aspx  
4 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20132202/summary  

4 

 
 
 
 
                                                      
Specific results 

As regards monitoring of drinking patterns and alcohol-related harm, the action: 

a)  Provided  a  baseline  assessment  and  suggestions  for  comparative  monitoring  of  alcohol 
epidemiology5  (HARMES  –  harmonising  alcohol-related  measures  in  European  surveys), 

including drinking levels and patterns and alcohol-related harm across the EU. Data collected from 

24  surveys  completed  in  a  5-year  period  (2008-2012)  in  17  countries  were  pooled  in  a  shared 

database with over 300 000 records.  

b)  Designed and implemented a survey instrument (SEAS – standardised European alcohol survey) in 

20  European  countries  representing  all  European  regions.  The  survey,  carried  out  on  random 

samples of the general public aged 18-64, generated an integrated European database comprising 

over  32 000  interviews.  It  covered  alcohol  consumption,  risky  single-occasion  drinking,  the 

context  in  which  people  drink,  harm  from  others’  drinking,  attitudes  and  opinions  on  alcohol 

policy, and unrecorded alcohol supply.  

The action resulted  in a  summary  report, ‘Good  practice  principles in  the  use  of  drinking  guidelines’.  It 

also  identified  examples  of  readily  transferable  good  practice,  i.e.  practice  that  is  adaptable  to  other 

contexts and has been shown to be efficient and effective in influencing attitudes to and patterns of alcohol 

consumption. The examples of good practice in prevention programmes (public awareness, school-based 
interventions, and early interventions) were compiled to create a toolkit for evidence-based good practices6, 

which includes guidance on criteria of good practice approaches to reducing alcohol-related harm. 

2.  Joint action on nutrition and physical activity (JANPA)  

More information is available on the JA website7 and in Chafea’s Health Programme database8.  

Background information  

Within the general context of the 2014-2020 EU action plan on childhood obesity, JANPA was designed to 

help  stop  the  rise  in  overweight  and  obesity  in  children  and  adolescents  by  2020.  24  EU  countries 

participated, either as partners or as collaborating stakeholders, including the World Health Organization’s 

5http://www.rarha.eu/Resources/Deliverables/Lists/Work%20Package%204/Attachments/7/Comparative%20monitori
ng%20%20of%20alcohol%20epidemiology%20%20across%20the%20EU%2019.08.pdf  
6http://www.rarha.eu/Resources/Deliverables/Lists/Work%20Package%206/Attachments/10/RARHA_Toolkit_WP6.
pdf  
7 www.janpa.eu/ 
8 https://webgate.ec.europa.eu/chafea_pdb/health/projects/677063/summary  

5 

 
 
                                                      
Regional Office for Europe and the Commission’s Joint Research Centre (JRC). The EU contribution was 

EUR 1 200 000.  

Brief description of activities 

JANPA  comprised  four  technical  work  packages,  each  involving  7-14  countries,  and  focused  on  the 

following activities:  

 

 

the use of economic evaluations of the cost of child obesity, to spur public action;  

the  sharing  of  specific  tools  to  promote  improvement  of  the  nutritional  quality  of  foods  and  of 

consumer information at national level; 

 

the identification and sharing of integrated actions at local or national level for diet and physical 

activity, prioritising children, families and professionals as the main participants in the actions, and 

pre-school and school settings as the main place to take action. 

Specific results 

JANPA mapped the sources and types of food information presentation currently available to consumers, 

analysed the use of food information in nutrition policy and presented the use and understanding of food 

information  by  families.  The  work  produced  by  JANPA  in  this  area  provided  useful  information  to  the 

European Commission for its work supporting food reformulation, and best practices identified in this area 

were also transferred to many interested EU countries through other actions. 

The  JA  produced  a  set  of  good  practice  criteria  for  childhood  obesity  prevention  in  kindergartens  and 

schools, with particular attention paid to the issues of sustainability and inequalities in health. The criteria 

were compiled in a web-based toolbox for programme planners and decision-makers, supporting them in 

their efforts to design and implement effective interventions. 

6 

 
 
 
 
Objective 3. Contribute to innovative, efficient and sustainable health systems 

3.  Joint action to support the eHealth network (JAseHN) 

For more information, see the JA website9 and Chafea’s Health Programme database10.  

Background information 

The JA was the main preparatory body for the  eHealth network, established by EU legislation on cross-
border  healthcare11.  More  specifically,  it  was  tasked  with  developing  political  recommendations  and 

instruments  supporting  the  electronic  exchange  of  health  data  in  four  priority  areas,  as  specified  in  the 

eHealth  network's  multiannual  work  plan  for  2015-2018:  (i)  interoperability  and  standardisation;  (ii) 

monitoring  and  assessment  of  implementation;  (iii)  exchange  of  knowledge;  and  (iv)  global  cooperation 

and positioning. 

The JA brought together ministries, national competent authorities or executive agencies, and other public 

bodies from 26 EU countries, the UK and Norway. The EU contribution was EUR 2 400 000. 

Brief description of activities 

JAseHN had already updated existing guidelines on the use of which form the health data exchange under 

the eHealth Digital Service Infrastructure (eHDSI). These are the patient summary for unscheduled care, 

ePrescription and eDispensations. 

JAseHN  also  cooperated  closely  with  the  bodies  implementing  the  eHDSI.  It  facilitated  the  application 

process  for  funding  from  the  Connecting  Europe  Facility  (CEF)  Telecom  programme  for  21  Member 

States. It also helped the EU countries prepare for participation in CEF calls by providing frameworks and 

policy documents linked with the preparation, deployment and operation of the national contact point for 

eHealth.  

JAseHN  also  facilitated  a  legal  agreement  between  national  authorities  or  national  organisations 

responsible  for  national  contact  points  for  eHealth  that  serves  as  the  basis  for  the  facilitation  of  cross-

border exchange of personal health data. 

9 https://jasehn.eu/  
10 https://webgate.ec.europa.eu/chafea_pdb/health/projects/677102/summary  
11  Directive  2011/24/EU  of  the  European  Parliament  and  of  the  Council  of  9  March  2011  on  the  application  of 
patients’ rights in cross-border healthcare (OJ L 88, 4.4.2011, p. 45). 

7 

 
 
 
 
                                                      
Specific results  

JAseHN delivered 37 policy documents to the eHealth network, most of them supporting the establishment 

of  the  eHDSI  launched  in  the  beginning  of  2017.  This  effort  has  made  the  cross-border  exchange  of 

information  operational 

through 

three  key  documents:  patient  summaries,  ePrescriptions  and 

eDispensations. 

What  this  means  in  practice  is  that  each  patient’s  essential  health  data  can  be  accessed  by  health 

professionals anywhere in the EU. This makes it easier for patients to travel within the EU, especially if 

they need to access emergency care. Patients moving to another EU country can expect to receive similar 

medication to that in their home country, thanks to ePrescriptions and eDispensations: the first enables a 

prescription to be sent electronically to a pharmacy, while the second refers to the electronic retrieval of a 

prescription and the provision of the prescribed medicine to the patient. 

JAseHN  has  successfully  fulfilled  its  purpose,  i.e.  providing  the  support  services  needed  to  set  up  an 

operational  framework  for  exchanging  cross-border  health  data  across  the  EU,  contributing  to  ongoing 

positive and dynamic development, and enabling the eHealth network to focus on future implementation 

and sustainability challenges. 

Objective 4 - Facilitate access to better and safer healthcare for Union citizens 

4.  Strengthening  cooperation  to  operate  pharmacovigilance  in  Europe 

(SCOPE) 

More information is available on Chafea’s Health Programme database12 and in a peer-reviewed article that 
appeared on the website of the US National Center for Biotechnology Information (NCBI)13.  

Background information  

The JA for SCOPE brought together national medicines regulators from 24 EU countries, Norway, Iceland 

and the UK to develop guidance and training in key aspects of pharmacovigilance, and tools and templates 

to support best practice. The EU contribution was EUR 3 300 000. 

The JA supported pharmacovigilance operations in the European network, minimised duplication of work 

and made the best use of work sharing and resources. One of the project’s key aims was to help national 

12 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20132102/summary  
13 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223699/  

8 

 
 
                                                      
competent  authorities  with  fewer  resources  to  develop  skills  and  capacity  in  pharmacovigilance,  and 

thereby help safeguard public health both at country level and in the EU as a whole. 

Brief description of activities 

The  JA  collected 

information  and  expertise  on  how  national  regulators  run 

their  national 

pharmacovigilance systems to meet the requirements of the pharmacovigilance legislation that took effect 

in June 2012. The SCOPE JA evaluated current practices and developed tools to further improve skills and 

capability  within  the  wider  pharmacovigilance  network,  including  through  the  involvement  and 

contributions of stakeholders such as patients and the pharmaceutical industry. 

Divided  into  five  core  work  streams,  SCOPE  delivered  best  practice  guidance,  tools  and  templates  and 

training  on  key  aspects  of  pharmacovigilance  in  the  following  key  areas:  (i)  collecting  information  on 

suspected adverse drug reactions; (ii) identifying and managing safety issues (signals); (iii) communicating 

risk; (iv) assessing risk minimisation measures; (v) effective quality management systems.  

The  deliverables  provide  practical  guidance  and  support  to  the  European  national  competent  authorities, 

helping them strengthen their national systems.  

Specific results  

The  work  on  collecting  information  on  adverse  drug  reactions  focused  on  national  schemes  for 

spontaneous  reporting  by  healthcare  providers  and  patients  and  provided  national  competent  authorities 

with  a  better  understanding  of  available  systems  and  practices  for  collecting  adverse  drug  reactions.  An 

EU-wide  social  media  campaign,  launched  to  raise  awareness  of  national  systems  for  reporting 

spontaneous  adverse  drug  reactions,  reached  more  than  2.5  million  people.  The  work  on  signal 

management improved understanding of this area within the EU network of national competent authorities, 

developed best practices in signal management and provided training to national medicines regulators. 

The  work  on  risk  communication,  which  focused  on  mapping  current  practices  in  the  EU  network, 

improved  understanding  of  communication  channels,  tools  used  and  the  effectiveness  of  the  various 

strategies  and  methods.  The  work  on  quality  management  systems  developed  tools  to  support  quality 

standards in pharmacovigilance systems and to increase existing knowledge through a training programme. 

The work on lifecycle pharmacovigilance explored existing standards for pharmacovigilance assessments 

and  examined  the  availability  and  use  of  alternative  data  sources  (other  than  spontaneous  reports)  for 

pharmacovigilance assessments in various European national competent authorities. 

9 

 
 
The  SCOPE  outputs  have  been  extremely  useful  to  other  stakeholders  involved  in  pharmacovigilance 

activities,  including  the  pharmaceutical  industry,  healthcare  professionals,  patient  and  consumer 

organisations,  and  academia.  The  SCOPE  training  materials  and  outputs  are  publicly  available  for 

interested  parties  to  use  and  implement  according  to  their  needs.  In  addition,  a  sustainable  solution  has 

been found for using and, as necessary, updating the deliverables: the learning materials are transferred to 

the EU Network Training Centre, a  joint training initiative endorsed by the heads of medicines agencies 

and the European Medicines Agency.  

10 

 
 
 
PROJECTS 

Objective  1.  Promote  health,  prevent  diseases  and  foster  supportive  environments  for  healthy 
lifestyles 

1.  Tobacco cessation guidelines for high-risk groups (TOB.g) 

More information is available on the project website14 and in Chafea’s Health Programme database15. 

Background information  

Tobacco use is one of the leading causes of premature death and disability in Europe. It also exacts a heavy 

economic toll on the European healthcare system, with direct healthcare costs alone estimated at EUR  1 

900 billion. Certain subgroups or populations are especially vulnerable and more sensitive when exposed 

to tobacco use. The TOB.g project developed and implemented an innovative and cost-effective approach 

to preventing chronic diseases associated with tobacco dependence and also to helping health professionals 

provide  guidance  and  target  prevention  to  high-risk  populations.  The  project  brought  together  partners 

from four EU countries and received an EU contribution of EUR 541 890.80. 

Brief description of activities 

The action targeted five high-risk groups. These were cardiovascular disease patients, chronic obstructive 

pulmonary disease patients, adults suffering from type 2 diabetes, adolescents and pregnant women. Given 

the  relative  shortage  of  tobacco  cessation  specialists,  the  action  provided  training  to  primary  care 

physicians to help make quality advice on tobacco cessation and support more accessible. 

The action established five scientific groups of health professionals with different types of expertise. Each 

group performed a situation analysis and assessment of the high-risk groups to develop bespoke, targeted 

tobacco cessation guidelines.  

Drawing on the evidence-based tobacco cessation good practices of the European network for smoking and 

tobacco prevention (ENSP), the guidelines were validated before the implementation of the pilot got under 

way.  Pilot  implementation  of  the  TOB.g  project  guidelines  in  turn  allowed  their  effectiveness  and 

usefulness to be assessed.  

Specific results 

14 http://tob-g.eu/  
15 https://webgate.ec.europa.eu/chafea_pdb/health/projects/664292/summary  

11 

 
 
                                                      
The  TOB.g  project  enabled  health  professionals  to  improve  their  knowledge  of  tobacco-related  health 

risks. Moreover, better knowledge enables improved prevention of chronic diseases by adapting smoking 

cessation tools that are appropriately assessed and tailored to the specific needs of high-risk groups. 

The  e-learning  course  and  training  sessions  developed  through  the  project  are  easily  transferable  to 

everyday clinical practice and techniques, thus improving access to specialised support and expert advice 

for  high-risk  groups.  Finally,  the  approach  of  targeting  primary  care  physicians  is  consistent  with 

recognising the important role that primary care can play in disease prevention and control. 

2.  Reference  Sites  Network  for  Prevention  and  Care  of  Frailty  and 
in  community-dwelling  persons  from  EU 

Chronic  Conditions 
countries (SUNFRAIL)  

More information is available on the project website16 and in Chafea’s Health Programme database17.  

Background information (policy priority, partnership and budget) 

The  project’s  overall  objective  was  to  promote  independence  for  ageing  elderly  people,  encouraging 

autonomy,  empowerment  and  commitment  to  the  community.  SUNFRAIL  was  also  designed  to  help 

decision-makers  and  health  service  providers  adopt  effective  policies,  strategies  and  care  pathways, 

bridging the gap between people’s needs and the services on offer. 

The  SUNFRAIL  project  designed  an  integrated  model  to  improve  the  identification,  prevention  and 

management of frailty and the care of multimorbidity in people aged over 65 living in communities in EU 

countries. 

The consortium,  coordinated  by  the  Emilia-Romagna  Region  (Italy),  brought together  11  partners  of  the 

European Innovation Partnership on Active and Healthy Ageing from five EU countries  and the UK. The 

EU funding was EUR 886 193. 

Brief description of activities 

The project mapped existing practices in the areas of risk assessment and the identification of frailty, based 

on several analytical tools. It developed a ‘SUNFRAIL model of frailty and multimorbidity’. This model is 

an  easy-to-use  tool  with  nine  questions  designed  to  identify  early  onset  of  frailty  and  multimorbidity  in 

three domains: biological (physical), psychological (cognitive and psychological), and social. 

16 http://www.sunfrail.eu/  
17 https://webgate.ec.europa.eu/chafea_pdb/health/projects/664291/summary 

12 

 
 
                                                      
The  tool  was  tested  on  adults  over  65  in  11  regions  across  Europe.  The  main  outcomes  were  reduced 

hospital and emergency admissions for ambulatory care for people with sensitive conditions. 

Specific results 

The main results confirmed that the tool was suitable for identifying the early onset of frailty and related 

risks in elderly people (over 65) with multimorbidity, especially in primary care and community settings. 

The tool appears particularly well suited to identifying frailty risks in a population without clear signs of 

disability, or that is not identified as frail by the health services of the regions taking part. The intervention 

was  therefore  tailored  to  guiding  the  target  population  of  elderly  people  to  appropriate  preventive  care 

pathways, thus reducing visits to hospital services. 

Finally, the project consortium also tested the adaptability, usability and adoption of the ‘SUNFRAIL tool’ 

in the countries where the model was implemented, to verify its potential for reproducibility in other EU 

countries. The tools showed a high level of transferability, especially when linked to other risk assessment 

and risk stratification strategies. 

Objective 2. Protect Union citizens from serious cross-border health threats 

3.  Operational  knowledge  to  improve  the  early  diagnosis  and  treatment  of  HIV 

among vulnerable groups in Europe (Euro HIV EDAT)  

More information is available on the project website18 and in Chafea’s Health Programme database19. 

Background information  

The  number  of  new  HIV  diagnoses  continues  to  rise  in  many  European  countries,  with  the  epidemic 

largely concentrated in certain sub-populations, namely MSM (men who have sex with men), who account 

for the highest proportion of diagnoses, and migrants. Recent data estimates that in EU countries, 30% of 

those  infected  are  unaware  of  their  infection  and  that  many  patients  diagnosed  with  HIV  start  treatment 

over a year after diagnosis. 

The  populations  most at risk  of  becoming  HIV  infected  are  also  difficult  to  reach  in  healthcare settings. 

Community-based voluntary counselling and testing services (CBVCTs) have therefore been identified as 

key  to  increasing  early  HIV  diagnosis  and  treatment,  provided  that  they  are  tailored  specifically  to  the 

target population and local context. 

18 https://eurohivedat.eu/ 
19 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20131101/summary  

13 

 
 
                                                      
The  action  brought  together  14  organisations  from  9  EU  countries,  including  both  non-governmental 

organisations (NGOs) and government agencies. EU funding was EUR 1 179 927. 

Brief description of activities 

The project’s overall aims  were to generate operational knowledge to improve understanding of the role 

and impact of CBVCTs across Europe, explore the use of innovative strategies based on new technologies, 

and increase early HIV/STI diagnosis and treatment among the groups worst affected.  

The project sought to generate harmonised monitoring and evaluation data from CBVTCs across Europe, 
using the indicators and data collection instruments developed by the HIV-COBATEST20 project, and to 

explore  the  acceptability,  feasibility  and  effectiveness  of  innovative  strategies.  Such  strategies  included 

point-of-care  technologies  for  HIV  and  STI  diagnosis,  HIV  self-testing  and  web-based  outreach  and 

counselling approaches. 

An internet-based toolkit was developed to support recently established NGOs and/or those wanting to start 

a CBVCT service/checkpoint for MSM (http://www.msm-checkpoints.eu/). It includes the main Euro HIV 

EDAT project products. The action also: 

  Monitored and evaluated the community-based voluntary HIV counselling and testing activities of 

the 41 services/networks. It also tested data from 168 409 clients tested for HIV in these CBVCT 

services/networks.  

  Updated the document ‘A guide to do it better in our CBVCT centres’ and developed a new tool 

for self-evaluation, to identify barriers to and facilitators for the implementation of good practices 

in CBVCT. 

  Established a cohort of seronegative patients for HIV MSM (COBA-Cohort). This cohort collects 

common data among 4 145 HIV-negative MSM attending 17 CBVCT services in 6 countries. 

  Performed  a  qualitative  and  a  quantitative  study  to  describe  different  mechanisms  of  linkage  to 

care  used  by  CBVCTs  and  their  acceptability,  feasibility  and  effectiveness  among  managers  and 

clients.  

  Conducted a qualitative and a quantitative study describing the use of testing and care services for 

HIV/STI  by  migrant  populations,  and  barriers  to  using  them  among  such  populations,  in  the 

participating  countries.  The  ‘Guide  to  best  practices  to  improve  earlier  testing  and  care  among 

migrant populations in Europe’ was published on the basis of these results. 

20 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20091211/summary  

14 

 
 
                                                      
  Carried  out  two  studies  to  evaluate  the  acceptability  and  foreseeable  impact  of  innovative  HIV 

testing  strategies  among  potential  users  and  stakeholders:  (i)  an  online  survey  among  MSM 

recruited  online  and  (ii)  an  online  study  among  key  stakeholders  involved  in  the  diagnostic 

process.  

 

Implemented  a  pilot  intervention  to  assess  the  acceptability  and  feasibility  of  an  outreach 

intervention for HIV testing among MSM and migrants and online communication of test results in 

six EU countries (Belgium, Spain, Portugal, Denmark, Romania and Slovenia). A separate website 

was developed to make test results available (www.swab2know.eu). 

Specific results 

Guidelines and manuals were developed for MSM and migrants, two of the groups worst affected by the 

HIV/STI epidemics in Europe.  

The  project  helped  improve  CBVCT  services  and  inform  policy-makers,  enabling  them  to  contextualise 

these interventions better within their national HIV prevention programmes. Crucial data was provided to 

improve the design of preventive interventions and thereby boost test uptake among MSM and migrants.  

The  project  generated  information  on  the  acceptability,  feasibility  and  effectiveness  of  innovative 

interventions  as  self-testing  and  outreach  interventions  and  on  the  use  of  new  technologies  to  provide 

results and counselling. 

The  project  thus  contributed  to  better-informed  policymaking,  reduced  transmission  of  HIV  and  other 

STIs, and improved clinical outputs of HIV and STIs patients across Europe. 

15 

 
 
 
 
Objective 3. Contribute to innovative, efficient and sustainable health systems 

4.  Statistical data and guidance document for medicinal product pricing and for the 

use of external reference pricing (EURIPID) 

More information is available on the project website21 and in Chafea’s Health Programme database22. 

Background information  

EURIPID  cooperation  is  based  on  voluntary  and  strictly  non-profit  cooperation  between  national 

competent authorities for the pricing and reimbursement of medicinal products, most of them in the EU. 

EURIPID is in the process of building up and maintaining a database of information on national prices and 

regulations on the pricing of medicinal products in a standardised format. Based on cooperation that started 

in 2010 between the Hungarian National Institute of Health Insurance Fund Management and the Austrian 

Public  Health  Institute,  the  project  currently  covers  data  from  more  than  26  European  countries.  It  is 

managed by four Member States and receives EU co-funding of EUR 299 999.70. 

Brief description of activities 

The  EURIPID  database  contains  data  on  the  official  prices  of  publicly  reimbursed,  mainly  outpatient 

medicinal  products,  as  published  by  national  authorities  in  line  with  the  Transparency  Directive 

(89/105/EC). The action encompasses regular maintenance tasks, developing a new database interface and 

predefined  queries,  an  improved  search  function,  user-reported  errors,  a  new  country  background 

information  system  and  several  other  functionalities  which  boost  user  experience  and  make  database 

management easier.  

The data  content  of the  EURIPID  database  was  also  extended  by  making  available information on  sales 

volumes  and  on  the  existence  of  managed  entry  agreements.  This  enabled  authorities  to  obtain  price 

information  in  a  more  efficient  way,  reducing  the  risk  of  making  decisions  based  on  incorrect  or 

incomplete data. 

Specific results 

Through  cooperation  with  all  relevant  stakeholders,  EURIPID  has  developed  a  technical  guidance 

document  on  a  coordinated  approach  by  national  authorities  to  the  use  of  ‘external  reference  pricing’ 

(ERP),  which  uses  medicinal  product  prices  from  other  countries  to  obtain  a  ceiling  price.  Thiso 

21 www.euripid.eu 
22 https://webgate.ec.europa.eu/chafea_pdb/health/projects/664317/summary  

16 

 
 
                                                      
avoids/mitigates potential negative impact on patients’ access to medicines. The document is available to 

national authorities and, in part, to the general public. 

This grant was followed by a new grant in early 2019 that is designed to (i) further expand the information 

provided  on  the  existence  of  managed  entry  agreements,  prices  and  sales  volumes  of  reimbursable 

medicinal products, (ii) improve services to users and the general public and (iii) strengthen cooperation by 

creating a platform for dialogue with stakeholders. Thanks to this cooperation, the recommendations in the 

technical guidance document on ERP will be more widely shared. 

17 

 
 
 
 
5.  BRidging  Information  and  Data  Generation  for  Evidence-based  Health  Policy 

and Research (BRIDGE Health)  

More information is available on the project website23 and in Chafea’s Health Programme database24.  

Background information 

Health policy and decision-making must be based on robust evidence in the form of high-quality, timely 

data on population health and health systems and the outcomes of thorough research. 

The  BRIDGE  Health  project  was  co-funded  by  the  EU  to  provide  a  baseline  for  such  data  and  create 

European  health  information  and  data  generation  networks  covering  major  EU  health  policy  areas.  The 

partnership  brought  together  31  partners  from  14  EU  countries,  Norway  and  the  UK,  receiving  EU  co-

funding of EUR 3 473 044.23. 

Brief description of activities 

BRIDGE  Health  developed  a  blueprint  to  integrate  health  care  information  systems  with  the  aim  of 

providing a European research infrastructure consortium on health information. 

The  project  addressed  the  EU  countries’  health  information  needs.  More  specifically,  helped  the 

participating  countries  ensure  that  data  on  health  information  needs  (i)  is  available  at  EU,  national  and 

subnational level, including information on social inequalities and vulnerable groups, (ii) are structured and 

comparable,  (iii)  include  information  about  key  determinants  of  ill  health,  (iv)  include  information  on 

healthcare systems and (v) build on information derived from best practice. 

Specific results 

The  project  delivered  a  feasibility  analysis  for  a  sustainable  European  health  information  structure.  It 

included scope, tasks, activities and governance structure, and the possible strengths and limitations of a set 

of possible structures including a European research infrastructure consortium on health information.  

23 http://www.bridge-health.eu/  
24 https://webgate.ec.europa.eu/chafea_pdb/health/projects/664691/summary  

18 

 
 
 
 
                                                      
Objective 4. Facilitate access to better and safer healthcare for Union citizens 

6.  European  Expert  Paediatric  Oncology  Reference  Network  for  Diagnostics  and 

Treatment (ExPO-r-Net)  

More information is available on the project website25 and in Chafea’s Health Programme database26. 

Background information  

Childhood  cancer  is  rare,  affecting  one  in  approximately  500  children,  with  multiple  subtypes  defined 

clinically and by biology that are relevant for specialist diagnostics and treatment. There is a clear need for 

certified  and  recognised  European  diagnostic  and  complex  treatment  reference  networks.  Paediatric 

oncology European clinical trial groups have been building cancer-specific cross-border networks in recent 

decades.  With  ExPO-r-Net,  a  focused  initiative  was  started  to  connect  existing  networks  better  and  to 

improve  the  visibility  of  hospitals  with  high-level  expertise  on  special  diagnostic  needs  and/or treatment 

interventions. 

The project brought together 18 partners from 8 Member States and the UK, and received EU funding of 

EUR 1 499 343. 

Brief description of activities  

ExPO-r-Net tackled inequalities in childhood cancer survival rates and healthcare capabilities in different 

Member  States,  and  took  the  first  steps  towards  improved  access  to  high-quality  healthcare  for  children 

with cancer whose conditions require specialised resources or expertise that are not widely available due to 

low case volumes and lack of local resources.  

ExPO-r-Net initiated cooperation between healthcare systems based on the existing networks of paediatric 

oncology European clinical trial groups. The aim was to achieve cost-effective, high-quality cross-border 

healthcare. Further, ExPO-r-Net identified target patient groups at risk who would benefit from access to 

concentrated expertise and resources. 

The ExPO-r-Net project built a pilot paediatric oncology ERN providing the essential conditions for cross-

border healthcare, the aim being to enable children and young people with cancer to receive care in another 

Member  State.  An  important  step  was  identification  and  quality  control  actions  targeting  healthcare 

25 https://www.expornet.eu/  
26 https://webgate.ec.europa.eu/chafea_pdb/health/projects/20131207/summary  

19 

 
 
                                                      
providers in countries with low expenditure rates on healthcare, where childhood cancer outcomes are 10-

20% below the western European average. 

Because of the potential burden on families seeking cross-border healthcare – i.e. leaving their supportive 

family and language environment and entering social isolation for treatments that may last many months – 

ExPO-r-Net  sought  mechanisms  to  facilitate,  whenever  possible,  the  movement  of  information  and 

knowledge rather than patients.  

Specific results 

ExPO-r-Net  fostered  access  to  expedited  expert  diagnosis,  described  and  identified  childhood  cancer 

patients  in  need  of  high-level  treatment  interventions  and  specialised  care,  identified  reference  centres 

across Europe for the paediatric oncology ERN (ERN-PaedCan), and initiated, coordinated and encouraged 

the establishment of international and national tumour boards at coordination hubs. A routing contact point 

was established to guide requests to the right forum.  

An  e-health-based  interoperability  strategy  was  developed  with  e-health  based  IT  tools,  making  it  easier 

and safer to interact. It launched an identification and self-evaluation process and gathered the information 

in a manual defining terminology and definitions for use in future certification processes describing quality 

criteria.  

ExPO-r-Net also encouraged measures to summarise treatments in a standard way in a survivor’s passport 

model  for  every  European  childhood  cancer  survivor.  It  also  advised  on  risk-based  appropriate 

surveillance. The late effect advisory board platform within the PanCare community enabled the creation 

of a central point of reference to help healthcare professionals understand and treat late cancer treatment-

related effects better. 

20 

 
 
 
 
OPERATING GRANTS 

The 17 NGOs that signed a framework partnership agreement (FPA) in 201727 were asked to submit their 

proposals for a specific grant agreement (SGA) to cover their 2018 recurrent operational expenses. 

The  FPAs  and  their  SGAs  helped  achieve  three  of  the  third  health  programme’s  objectives.  13  NGOs 

tackled  objective  1,  ‘Promote  health,  prevent  diseases  and  foster  supportive  environments  for  healthy 

lifestyles’,  1  worked  on  objective  3,  ‘Contribute  to  innovative,  efficient  and  sustainable  health  systems’, 

and 3 focused on objective 4, ‘Facilitate access to better and safer healthcare for Union citizens’. 

Table 1: List of applicant organisations awarded an FPA 2017-2021 and subsequent SGAs  

Acronym/ abbreviation  Action title/ beneficiary organisation 

CN 

AE 

Correlation network for harm reduction and social inclusion 

Alzheimer Europe  

OBTAINS-E2 

Obesity training and information services for Europe (World Obesity Federation) 

EPHA  

AAE 

EUPHA 

THALIA 

European public health alliance multiannual work programme 

Stronger Together (Aids Action Europe) 

European Public Health Association 

THALassaemia In Action (Thalassaemia International) 

EuroHealthNet 

Strengthening action on health promotion and health equity in the EU  

EHN 

SFP  

ENSP  

HAI 

SHE  

SAVDON 

ECL  

TBEC 

EURORDIS 

European heart network - fighting heart disease and stroke 

Smoke-free partnership coalition’s multiannual work plan  

European network for smoking and tobacco prevention - The Network - United for 
a tobacco-free Europe 
A plan for action: ensuring equitable, affordable and responsibly used medicines in 
the European Union (Health Action International) 

Schools for health in Europe network foundation 

High-quality blood stem cell products available for all patients in need, while 
protecting the rights and welfare of the volunteer donors (World Marrow Donor 
Association) 
European cancer leagues - cooperating for impact on cancer control 

Strengthening the capacity and capability of civil society to drive the TB response 
in Europe 
EURORDIS - the voice of rare disease patients in Europe 

Thematic 
priority 
1.1 

1.1 

1.1 
1.1 
1.1 
1.1 
4.2 
1.1 

1.1 
1.1 
1.1 

3.6 

1.1 
4.5 

1.1 

1.1 

4.2 

Throughout 2018, in line with their SGAs, the organisations achieved their objectives, did valuable work 

for their stakeholders and supported Commission health policy initiatives in their areas of activity.  

27 A total of 17 FPAs covering 2017-2021 were signed with successful applicant organisations, resulting in eligibility 
for financial support on an annual basis for each of the years covered by the FPA. 

21 

 
 
 
                                                      
Below  we  present  the  work  and  outcomes  of  three  organisations  active  in  cancer  prevention:  the 

Association of European cancer leagues (ECL), the smoke-free partnership (SFP) coalition, and the ENSP. 

All three are examples of EU umbrella networks supported by the EU health programme.  

1.   European cancer leagues cooperating for impact on cancer control  

More  information  about  the  association  of  European  cancer  leagues  is  available  on  the  organisation’s 
website28 and in Chafea’s Health Programme database29.  

Background information 

Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths (22% of all deaths from 

non-communicable diseases) in 2012. In that year, there were 3.45 million new cases of cancer (excluding 
non-melanoma  skin  cancer)  and  1.75  million  deaths  from  cancer  in  Europe30.  In  the  EU,  new  cases  of 

cancer  were  estimated  at  1.4  million  in  males  and  1.2  million  in  females,  and  around  707 000  men  and 

555 000 women died of cancer in the same year.  

The association of ECL provides a unique platform, being the only organisation whose raison d’être is to 

bring  together  national  and  regional  cancer  leagues  at  pan-European  level  in  efforts  to  make  Europe 

cancer-free. It provides strategic added value by sharing good practice and providing input into EU policy 

development and implementation, through knowledge supplied by cancer leagues with first-hand practical 

experience.  

Under the 2018 SGA, the beneficiary received EU co-funding of EUR 302 895. 

Brief description of activities  

The overall objectives of the ECL’s SGA were to:  

  monitor EU cancer prevention, as well as EU legislation and policy action;  

 

 

continue working towards a tobacco-free Europe; 

explore  patient  issues  among  the  member  leagues  in  areas  in  which  the  ECL  can  make 

recommendations for use by leagues and at EU level, through the patient support working group 

(PSWG);  

 

advocate for equal access to medicines for cancer patients, through the ECL task force on access to 

medicines;  

28 https://www.europeancancerleagues.org/   
29 https://webgate.ec.europa.eu/chafea_pdb/health/projects/811112/summary  
30 Defined as the WHO European Region 

22 

 
 
                                                      
 

communicate and promote the implementation of the European code against cancer in cooperation 

with member leagues. 

Action  taken  by  the  ECL  in  2018  covers  the  whole  spectrum  of  cancer  control,  targeting  primary  and 

secondary  prevention  by  promoting  the  European  code  against  cancer  (ECAC)  and  tobacco  control 

advocacy. ECL’s sustained long-term focus on the ECAC has enabled more cancer leagues to develop their 

activities to promote the ECAC by sharing knowledge and experience with peers. It also conducted the first 

systematic evaluation of the ECAC’s impact, over 30 years after its initial publication. 

ECL  action  plan  methods  include:  (i)  holding  workshops  and  round-table  meetings;  (ii)  online 

communication, including social media; and (iii) surveys and study visits to enable cancer leagues to learn 

from their peers.  

The ECL coordination team supported cooperation with nominated representatives of cancer societies on 

prevention and tobacco control issues, and participation in EU fora and platforms such as the EU diet and 

physical activity platform and the European Commission initiative on breast cancer. 

Specific results 

The  ECL  organised  a  policy  dialogue  during  the  European  week  against  cancer;  stepped  up  action  on 

cancer screening by publishing a layman’s version of the recent EU cancer screening report and developed 

training for cancer leagues in this area. 

The  ECL  promoted  implementation  of  the  ECAC  by  networking  and  by  enhancing  the  role  played  by 

youth  ambassadors  in  these  efforts.  The  ECL’s  PSWG  and  task  force  on  access  to  medicines  have 

produced patient support guidelines.  

The  ECL  continued  to  support  EU  policy  through  the  ongoing  secretariat  function  of  the  European 

Parliament’s  successful  ‘MEPs  against  cancer’  group.  There  was  increased  demand  for  the  ECL  to 

organise events, both at the request of MEPs themselves and of other umbrella organisations. 

The ECL’s SGA delivered the following main outputs: 

- 

a guide for patients on how they can improve communication and obtain all the information they 

need when consulting healthcare professionals; 

- 

a guide for European cancer societies on how to develop and manage volunteers to provide patient 

support; 

- 

- 

a presentation for employers on how to handle cancer at the workplace; 

the sharing of best practice from various schemes in France and Belgium, to avoid discrimination 

against cancer survivors; 

23 

 
 
- 

a position paper stating cancer leagues’ priorities on European cooperation on health technology 

assessment (HTA); 

a toolkit for cancer societies on HTA; 

the publication of an article on pricing of CAR T-cell therapies; 

a White Paper on tackling challenges in access to medicines.  

- 

- 

- 

Several workshops and visits were organised to promote the ECAC, with more than 80% of participants 

later reporting that they were making active use in their daily work of what they had learned through these 

events.  

2.  Smoke-free partnership coalition: smoking prevention in action  

For more information about the work of the SFP coalition31, see the organisation’s website and Chafea’s 
Health Programme database32. 

Background information  

The SFP coalition’s overarching goal is to prevent cancer and chronic diseases through activities at EU and 

national level to support the prevention of smoking, focusing particularly on young people and health in all 

policies.  

To  achieve  its  mission,  the  SFP  mobilises  stakeholders  and  decision-makers  to  make  tobacco  control  a 

political  priority  in  Europe  and  advocates  for  evidence-based  tobacco control  policies. The  SFP  engages 

health  organisations, researchers  and international  networks  to  strengthen  the  global response to tobacco 

and support the implementation of the WHO framework convention on tobacco control (FCTC) in Europe. 

Under the 2018 SGA, the beneficiary received EU co-funding of EUR 419 906. 

Brief description of activities 

As an advocacy organisation, the SFP used a variety of appropriate methods to convey its key  message. 

These  included  factsheets,  myth-busting  documents,  briefings,  position  papers,  events  and  conferences, 

reports, website updates, joint coalition letters, press releases and statements, various toolkits, newsletters, 

presentations at Europe-wide and national conferences, Facebook status updates and Twitter feeds. 

The  SFP  also  worked  to  build  capacity  within  civil  society  and  to  help  coalition  members  prepare  for, 

coordinate and respond collectively to the possible revision of the Tobacco Tax Directive, 2011/64/EC. It 

31 https://www.smokefreepartnership.eu/  
32 https://webgate.ec.europa.eu/chafea_pdb/health/projects/747248/summary  

24 

 
 
                                                      
raised  awareness  among  policy-makers  and  civil  society  of  Article  20  (tobacco  research  policies)  of  the 

FCTC.  

The coalition also continued to raise awareness and support the ratification of the international protocol to 

eliminate  illicit  trade  in  tobacco  products.  It  strongly  supported  the  adoption  of  the  technical  standards 

underpinning  the  tracking  and  tracing  system  for  tobacco  products  in  the  EU,  in  line  with  the  relevant 
implementing and delegated acts33. Finally, SFP activities also targeted Article 5.3 of the FCTC regarding 

the protection of public policy from tobacco industry interference. 

Specific results 

The SFP coalition stepped up its cooperation and boosted its membership to the current total of 49 partners 

across Europe, broadening its scope for actions such as influencing tobacco control policies, reducing illicit 

trade,  increasing  financial  resources  for  tobacco  control  research,  and  increasing  the  overall  minimum 
excise duties on tobacco34.  

Two  major  events  were  held  in  2018:  one  on  tobacco  taxation  and  the  illicit  trade  in  tobacco  products, 

which  took  place  in  Sofia  under  Bulgaria’s  EU  Presidency,  and  the  other  a  meeting  marking  World  No 

Tobacco Day in the European Parliament. 

The SFP participated in the eighth session of the conference of the parties (COP8) and at the meeting of the 

parties (MOP1) of the illicit trade protocol in October 2018, ensuring regional coordination communication 

with the global team and its priorities, and successfully pursuing its advocacy of  civil society objectives. 

The  coalition  also  strongly  supported  the  first-ever  global  strategy  to  accelerate  tobacco  control  and  the 

roadmap for accelerated progress on tobacco control towards the achievement of sustainable development 

goal target 3a. 

In addition, SFP coalition members continued to share ideas and information, coordinate their efforts and 

engage  in  collective  advocacy  on  shared  objectives  and  campaigns,  thereby  advancing  tobacco  control 

policies  at  both  EU  and  international  level.  The  coalition  achieved  all  this  as  a  well-established, 

professional and well-respected network for the coordination of advocacy.  

33 https://ec.europa.eu/health/tobacco/tracking_tracing_system_en 
34  SFP’s  position  paper  –  ‘Tobacco  Tax  for  a  Healthier  Europe’:  https://www.smokefreepartnership.eu/news/sfp-
news/updated-sfp-position-paper-on-tobacco-taxation 

25 

 
 
                                                      
3.  European network for smoking and tobacco prevention (ENSP) 

– united for a tobacco-free Europe  

For  more  information  about  the  ENSP’s  work,  see  its  website35  and  Chafea’s  Health  Programme 
database36. 

Background information  

Based on its secretariat’s increased capacity for action, the ENSP made it a key task under the operating 

grant to  provide  local  help  to  its network  members  on  implementation  of  EU legislation  on tobacco  and 
related products37 at national level. 

It  also  focused  on  stepping  up  its  role  as  a  source  of  scientific  evidence  and  academic  research  for  its 

members, with a view to having a real impact on tobacco use in Europe. Under the 2018 SGA, it received 

EU co-funding of EUR 393 648. 

Brief description of activities 

The ENSP’s main activities are: 

-  working with local, regional and national players to support the implementation of the FCTC and the 

transposition of the EU Tobacco Products Directive into national law within the EU; 

- 

strengthening  the  network,  by  increasing  the  number  of  national  coalitions  and  their  pro-activeness, 

- 

- 

and by promoting links between members;  

becoming involved in Europe-wide projects; 

improving  internal  and  external  communication,  sharing  information  effectively,  and  building  the 

capacity of all members and stakeholders working on tobacco control in Europe; 

- 

building the organisation’s capacity and capability by consolidating the secretariat team, increasing the 

number of members, and reaching out to new sectors. 

35 ensp.network/   
36 https://webgate.ec.europa.eu/chafea_pdb/health/projects/881565/summary 
37 Directive 2001/37/EC of the European Parliament and of the Council of 5 June 2001 on the approximation of the 
laws, regulations and administrative provisions of the Member States concerning the manufacture, presentation and 
sale  of  tobacco  products  (OJ  L  194,  18.7.2001,  p.  26)  (more  widely  known  as  the  Tobacco  Products  Directive  or 
TPD) is the centrepiece of EU legislation in the area of tobacco control and tobacco market regulation.  

26 

 
 
 
 
                                                      
Specific results 

As a bridge and information platform between EU institutions and national members, the ENSP uses a mix 

of tools to disseminate, and keep the network up-to-date with, the latest developments in tobacco control 

issues. These include communication resources, presentations, information dissemination, meetings, events 

and write-ups. 

In 2018 the ENSP:  

(i) 

(ii) 

(iii) 

(iv) 

organised five major events;  

maintained its updated website;  

produced a monthly newsletter and increased frequency of publication;  

strengthened the position of its official scientific journal, ‘Tobacco Prevention and Cessation’; 

and  

(v) 

was very active on social media.  

It also conducted two expert support visits to France and Georgia, and took the lead on national advocacy 

campaigns. 

Through its new communication strategy, the ENSP produced a range of resources to boost recognition and 

awareness of the organisation among both members and wider stakeholders. It fundamentally strengthened 

its  role  as  a  capacity  builder  and  confirmed  its  position  in  the  research  arena  by  creating  a  new  peer-

reviewed journal and setting up a network of universities involved in tobacco control. 

27 

 
 
 
 
DIRECT GRANT AGREEMENTS WITH INTERNATIONAL ORGANISATIONS 

1.  OECD  health  workforce:  feasibility  study  for  an  international  survey  of  health 

workers’ skills  

More information about the health workforce report is available on the OECD’s website38. 

Background information  

The direct grant agreement explored the feasibility of carrying out a sector-specific survey on the skills of 

health professionals. It received EU co-funding of EUR 150 000. 

The  study  built  on  the  findings  of  a  previous  OECD  action,  ‘Overview  of  education  and  training 

programmes for health professionals in the EU’, which included an analysis of changes in education and 

training capacities in the EU and other OECD countries and identified a significant skills mismatch among 

doctors and nurses in the health sector. 

Brief description of activities 

The  OECD  undertook  extensive  consultations  with  key  stakeholders  and  experts  to  identify  the  priority 

policy questions and skill requirements for different categories of health professionals. It also reviewed the 

existing  data  sources,  including  international  surveys  and  profession-specific  surveys,  identified  the 

priority  skills  shared  across  all  categories  of  health  professionals  and  compared  the  various  survey 

instruments and analytical approaches used in previous skills assessment surveys in the health sector. 

Based  on  these  reviews,  the  OECD  proposed  a  general  competency  framework  and  a  set  of  transversal 

skills, including possible content areas (types of services, professional categories, domains of competence) 

and instruments (e.g. direct and indirect assessment tools) to be included in a survey of health workforce 

skills, and discussed various options for its implementation in terms of design and testing. 

Finally, it proposed the next steps for taking the findings of the feasibility study towards implementation at 

national and international levels. 

Specific results 

The  health  workforce  study  concluded  that  healthcare  professionals  need  to  apply  adaptive  problem-

solving skills to respond to complex and non-routine patient care issues, while working in complex, multi-

38http://www.oecd.org/health/health-systems/Feasibility-Study-On-Health-Workforce-Skills-Assessment-Feb2018.pdf 

28 

 
 
                                                      
disciplinary and frequently stressful occupational environments. In the coming years, countries will need 

resilient and flexible health workers who are armed not only with technical and clinical skills, but also with 

cognitive skills, self-awareness and social skills that will enable them to monitor and assess the situation, 

make  decisions,  take  a  leadership  role,  and  communicate  and  coordinate  their  actions  within  a  team  in 

order  to  achieve  high  levels  of  patient  safety  and  efficiency  and  ensure  their  own  safety  and  job 

satisfaction. The feasibility study was received with great interest among OECD member states during the 

OECD health committee meeting in December 2017, and a number of countries indicated their intention to 

adopt a number of its recommendations in their health workforce surveys.  

Dissemination  of  the  study  at  policy-relevant  debates  and  events  and  through  health  professional 

associations,  regulatory  bodies  and  patient  groups  helps  shape  policymaking  in  the  areas  of  skills 

assessment and development of relevant education, organisation and regulatory policies and reforms.  

2.  OECD - economic burden and health impact of antimicrobial resistance  

For more information about the economics of antimicrobial resistance (AMR), see the OECD’s website39.  

Background information 

The  direct  agreement  received  EU  funding  of  EUR 340  000  to  prevent  AMR  and  control  healthcare-

associated  infections.  This  action  supported  the  implementation  of  the  EU  strategy  to  combat  AMR, 

focusing  on  two  objectives:  the  development  of  a  model  to  analyse  the  economic  and  health  impact  of 

antimicrobial  resistance,    and  an  analysis  of  the  effectiveness  and  efficiency  of  potential  prevention  and 

control measures in the human sector. 

Brief description of activities 

The  main  activities  carried  out  with  the  help  of  this  grant  included  review  and  analysis  of  the  available 

econometric  models  evaluating  the  economic  implications  of  AMR.  This  work  made  it  possible  to  (i) 

identify the pros and cons of different approaches, (ii) contribute to the identification of underlying drivers 

of AMR and (iii) design the model. 

The work also included: 

39https://www.oecd-ilibrary.org/docserver/9789264307599-
en.pdf?expires=1583926955&id=id&accname=oid031827&checksum=7706E2ECF3790A1E6FAAFAA319FAA16F  

29 

 
 
                                                      
- 

reviewing and quantifying the related epidemiological inputs (e.g. incidence of AMR) and cost drivers 

(e.g.  longer  hospitalisation,  use  of  more  costly  drugs/medical  tests,  increased  mortality,  longer 

absenteeism from work) underlying the AMR burden; 

- 

identifying  key  interventions  to  tackle  the  burden  that  AMR  places  on  humans  (i.e.  preventing  new 

AMR  infections  through  appropriate  use  of  antibiotics  and  limiting  the  spread  of  existing  AMR 

infections),  extracting  the  evidence  to  model  such  interventions,  and  creating  a  taxonomy  of 

interventions; 

- 

developing  economic  and  epidemiological  model(s)  replicating  the  burden  of  AMR  (including  the 

consequences of routine use of antibiotics in modern healthcare) and calculating the effectiveness and 

efficiency of actions to tackle AMR in the human sector; 

- 

evaluating  the  effectiveness  and  cost-effectiveness  of  selected  interventions  to tackle  AMR  by  using 

the economic model developed. 

Specific results 

The key findings support three main packages of interventions that EU countries can implement to reduce 

the burden of AMR, as follows: 

-  The  first  package  addresses  the  hospital  setting  (including  improved  hand  hygiene,  stewardship 

programmes and enhanced environmental hygiene in healthcare settings). 

-  The  second  package  consists  of  community-level  actions  (including  delayed  prescriptions,  mass 

media campaigns and use of rapid diagnostic tests). 

-  The third package is a mixed intervention package (including stewardship programmes, enhanced 

environmental hygiene, mass media campaigns and the use of rapid diagnostic tests).  

According  to  the  final  report,  putting  these  packages  in  place  would  reduce  the  burden  of  disease  from 

AMR  by  85%,  23%  and  73%  respectively  and  would  also  achieve  annual  savings  per  capita  of  USD 

purchasing power parity (PPP) 4.1, 0.9 and 3 respectively. 

30 

 
 
 
 
CALLS FOR TENDERS 

1.   Further  development  and  implementation  of  the  ‘EU  compass  for  action  on 

mental health and wellbeing’  

Background information  

The mental health policy consortium (MHPol) was selected to implement the further development of the 

‘EU  compass’,  with  a  budget  of  EUR 800  000.  It  followed  up  the  work  of  the JA  on  mental  health  and 

wellbeing (JA-MHWB), and, more specifically, its final recommendations, summarised in a report entitled 

‘European framework for action on mental health and wellbeing’.  

Led by the Dutch Trimbos Institute, the consortium included the NOVA University of Lisbon, the Finnish 

Association for Mental Health, and EuroHealthNet. It collected, shared and analysed information on policy 

and stakeholder activities in mental health. 

Brief description of activities 

The  compass  disseminated  the  outcomes  of  the  JA  and  put  in  place  a  platform  to  monitor  and  analyse 

mental health and wellbeing policies and the activities of EU countries and non-governmental stakeholders. 

It further identified and disseminated good practices in Europe in the areas of mental health and wellness 

promotion and the prevention of mental disease.  

The  consortium  produced  four  thematic  position  papers  on  the  following  key  issues:  (i)  preventing 

depression and promoting resilience, (ii) improving access to mental healthcare services, (iii) mental health 

in  the  workplace  and  (iv)  providing  community-based  mental  health  services.  Finally,  it  also  conducted 

three  annual  surveys  for  Member  States  and  stakeholders,  and  organised  three  annual  forum  events  and 

several national workshops.  

Specific results 

During the implementation of the contract, the EU compass forum positioned itself as a substantial event in 

the European calendar. In its three annual fora it brought together all national and EU-level stakeholders 

representing  a  range  of  players,  including  the  governmental  sector,  NGOs  and  intergovernmental 

organisations,  academics  based  in  universities  and  research  centres,  organisations  of  service  users  and 

carers, European networks, professional associations, health service providers and stakeholders from other 

connected fields.  

31 

 
 
By  identifying,  assessing  and  disseminating  best  practices  among  Member  States,  it  made  a  key 

contribution  to  the  debate  on  mental  health  at  both  national  and  European  level.  This  helped  raise  the 

profile of mental health challenges in the EU public health agenda. The OECD flagged up mental health as 

a key issue in the ‘State of health in the EU’ cycle.  

Best  practices  validated  by  the  action,  such  as  the  iFightDepression  programme  (run  by  the  European 

alliance against depression) and the housing first programme (‘Casas primeiro’ in Portugal), were selected 
by  the  JRC40  during  a  marketplace  workshop  and  were  subsequently  included  among  those  to  be 

implemented under the AWP 2020, which is another clear sign of success. 

More  information  about  the  study  is  available  on  the  website  of  the  Directorate-General  for  Health  and 
Food Safety (DG SANTE)41.  

Request  for  specific  service  Chafea/2017/Health/18  for  the  organisation  of  the  tabletop  exercise  on 

hybrid threats involving public health and civil protection/security authorities – exercise chimera.  

Background information 

The ‘Chimera’ exercise focused on improving preparedness and strengthening the capacity to coordinate a 

response to hybrid threats: it was a table top exercise held in Luxembourg on 30-31 January 2018 by Public 

Health England, which received EU co-funding of EUR 229 209.  

Its main purpose was to bring together experts from the public health and civil protection/security sectors 

to  consider  the  coordinated  crisis  response  to  cross-border  hybrid  threats  facing  EU  and  European 

Economic  Area  (EEA)  countries,  other  countries,  EU  institutions  and  agencies  and  international 

organisations. 

Brief description of activities 

The  scenario  for  the  exercise  was  a  fictitious  terrorist  organisation  that  caused  an  outbreak  of  a 

communicable  disease  following  a  deliberate  release  and  undertook  concurrent  cyber-attacks  on  critical 

infrastructure including hospitals. 

The  main  objective  of  this  simulation  was  to  challenge  the  use  and  usability  of  existing  systems  and 

communications tools in response to a hybrid threat through 11 objectives.  

40 https://ec.europa.eu/health/non_communicable_diseases/events/ev_20190514_en  
41 https://ec.europa.eu/health/non_communicable_diseases/mental_health/eu_compass_en  

32 

 
 
                                                      
Over 80 experts from the health, civil protection and security sectors took part from 24 EU Member States, 

the  EEA  countries  Iceland  and  Norway,  and  Serbia  and  Moldova.  The  European  Commission’s  DG 

SANTE,  Secretariat-General  (SG),  Directorate-General  for  Migration  and  Home  Affairs  ,  Directorate-

General for European Civil Protection and Humanitarian Aid Operations , and the JRC were represented, 

as  were  the  European  Centre  for  Disease  Control  ,  the  European  External  Action  Service  (EEAS),  the 

Computer Emergency Response Team for the EU , the EU Hybrid Fusion Cell within the EU Intelligence 

and Situation Centre  of the EEAS, the Council of the EU, Chafea, the WHO and NATO. 

Specific results 

The  Chimera  exercise  provided  an  opportunity  for  participants  from  the  public  health  and  civil 

protection/security  sectors  to  come  together  and  engage  for  the  first  time  with  a  hybrid  threat  scenario. 

While  the  exercise  demonstrated  that  in  general  there  is  a  good  understanding  of  the  roles  and 

responsibilities  during  such  an  incident  and  a  high  level  of  awareness  of  the  reporting  systems  that  are 

available,  it  also  highlighted  that  further  work  is  required  at  Member  State  and  EU  levels  to  ensure 

interoperability between the various sectors. 

A  key  recommendation  was  that  regular  training  and  exercises  should  be  held  at  Member  State  and  EU 

level  in  order  to  improve  inter-sectoral  crisis  management  and  raise  awareness  of  the  range  of  the 

mechanisms  in  place  across  the  different  sectors  to  deal  with  threats.  Such  training  and  exercises  would 

raise  awareness  of  hybrid  threats  and  promote  an  understanding  of  how  they  differ  from  other  threats. 

Finally, it was suggested that best practice in preparedness and response from the most developed sectors 

could be shared at these events. 

More information about the study is available on DG SANTE’s website42.  

2.  Study on cross-border cooperation: capitalising on existing initiatives for cooperation in 

cross-border regions (request for specific services No Chafea/2016/Health/22)  

Background  

While  there  is  no  legal  obligation  for  Member  States  to  engage  in  cross-border  cooperation,  the  Cross-

Border  Care  Directive  (2011/24/EU)  tasks  the  Commission  with  encouraging  cooperation  between  EU 

countries and with taking, in close contact with them, any useful initiative to facilitate and promote such 

cooperation. 

42 https://ec.europa.eu/health/sites/health/files/preparedness_response/docs/2018_hybridthreatsexercise_en.pdf  

33 

 
 
                                                      
At the informal health ministerial meeting held in Luxembourg in September 2015, several Member States 

called  on  the  Commission  to  draw  up  an  exhaustive  overview  of  all  existing  cross-border  initiatives.  A 

study was therefore launched, carried out by a consortium led by Sogeti Luxembourg S.A. This received 

EU co-funding of EUR 254 570 to consolidate the scoping work and examine the question of cross-border 

cooperation, not solely but especially in border regions.  

Brief description of activities 

The  study  investigated  past  achievements  and  potential  future  developments  in  cross-border  healthcare 

cooperation. The findings were based on a mapping of cross-border healthcare initiatives funded by the EU 

health programme (e.g. project HonCAB on pilot hospital networks for payment of care for cross-border 

patients), foresight modelling for cross-border healthcare in 2030, a systematic literature review on fraud 

and fraud mitigation in cross-border healthcare, and an evaluation of the take-up of the JA on patient safety 

and quality of care (PaSQ). The study also provided practical tools to assist stakeholders including local 

and regional authorities intending to start a cross-border healthcare cooperation project.  

Specific results 

The  study,  which  deepened  understanding  of  cooperation  on  cross-border  healthcare,  provides  new 

information about various aspects of cross-border healthcare research. Seven lessons were summarised:  

1.  Cross-border  healthcare  initiatives  are  more  effective  in  regions  where  ease  of  cooperation  is 

already established, owing to similar welfare traditions or close historical ties, for instance.  

2.  Key players such as regional policy-makers or hospital managers should receive support, to reduce 

the transaction costs of cross-border healthcare. The toolbox developed in this study is a way of 

providing help. 

3.  There are several scenarios for future cross-border healthcare. One of the most realistic ones builds 

on regional networks oriented towards addressing local and regional needs.  

4.  Regional  networks  are  likely  to  represent  a  low-cost  option,  but  the  downsides  are  that  they  are 

likely to remain small-scale and they may create inequities by not benefiting all regions equally. 

5.  The  top  categories  of  cross-border  healthcare  initiatives  to  receive  EU  funding  over  the  past  10 

years  are  those  focused  on  knowledge  sharing  and  management,  and  on  sharing  treatment  and 

diagnosis of patients.  

6.  Forms of cooperation such as high-cost capital investments and emergency care tend to have more 

discernible economic and social benefits, but require more formalised terms of cooperation.  

7.  Although  information  on  the  effectiveness  and  sustainability  of  current  cross-border  healthcare 

initiatives is scarce, the funding of cross-border healthcare projects could help achieve these aims.  

34 

 
 
More information about the study is available on DG SANTE’s website43.  

3.  Provision  of  a  market  study  on 

telemedicine 

(request 

for  specific  services 

Chafea/2016/Health/17)  

Background 

Following up the mid-term review of the digital single market, which highlighted a strong willingness to 

facilitate  the  accessing  and  sharing  of  health  data  for  research  or  treatment  purposes,  the  Commission 

published a communication in 2018 on enabling the digital transformation of health and care in the digital 
single market44. 

In  support  of  the  above,  Chafea  procured  a  study  on  the  telemedicine  market  in  Europe  and  the  factors 

determining its development. PwC Luxembourg conducted the study for EUR 283 950. 

Brief description of activities 

The  analysis  mapped  telemedicine  applications  and  solutions,  and  applicable  technical  standards  and 

guidelines, and described the market dynamics and potential barriers that limit the wider deployment and 

uptake of telemedicine solutions in Europe.  

It also assessed the cost-effectiveness of a larger-scale deployment of telemedicine under current and future 

market conditions and provided relevant recommendations for policy-makers. 

The study identified and mapped successful existing initiatives which have already facilitated the adoption 

of telemedicine solutions.  

The  study  also identified  the  following  additional  interventions  needed  to  support  the  wider  deployment 

and uptake of telemedicine: (i) raising public awareness about the benefits of telemedicine, (ii) supporting 

large-scale  projects  where  telemedicine  can  be  tested  and  its  benefits  assessed  and  (iii)  legislative 

interventions  by  the  Commission  or  Member  States  to  address  some  of  the  barriers  to  adopting 

telemedicine in the EU. 

Specific results 

The key take-away points of the study are as follows: 

43 https://ec.europa.eu/health/sites/health/files/cross_border_care/docs/2018_crossbordercooperation_frep_en.pdf 
44 Communication from the Commission to the European Parliament, the Council, the European Economic and Social 
Committee and the Committee of the Regions on enabling the digital transformation of health and care in the Digital 
Single Market; empowering citizens and building a healthier society, COM(2018) 233.  

35 

 
 
                                                      
  Both the market potential and the cost-effectiveness, if properly applied, of telemedicine solutions 

can support the overall efficiency and resilience of health systems in the EU. 

  The lack of a common legal framework reinforces the other underlying obstacles (reimbursement, 

lack of interoperability, lack of acceptance) to the development of telemedicine.The EU has a key 

role to play in supporting the Member States as they set their own national standards, both at the 

regulatory and the technical levels. 

  The  EU  can  minimise  regulatory  fragmentation  through  the  support  for  a  common  approach 

among national standards setting bodies and regulators responsible for the different components of 

telemedicine systems; 

 

It should ensure common interoperability solutions to enhance the cross-border use of the various 

telemedicine applications and solutions and the data they generate. 
More information about the study is available on DG SANTE’s website45.  

45 https://ec.europa.eu/health/sites/health/files/ehealth/docs/2018_provision_marketstudy_telemedicine_en.pdf  

36 

 
 
 
 
                                                      
HIGHLIGHTS OF CO-FUNDED ‘CROSS-CUTTING’ AND ‘OTHER’ ACTIONS 

1.  Dissemination activities carried out in 2018 

The  dissemination  actions  carried  out  in  2018  focused  on  communication  priorities  indicated  by  DG 

SANTE  (such  as  vaccination),  the  European  reference  networks  (ERNs)  for  rare  diseases,  health 

technology assessment, crisis preparedness in health, medical devices, and combating AMR, 

Activities associated with the ERNs included:  

-  publishing an e-booklet on rare diseases46; 
-  publishing an info sheet on ERNs’ results after their first year of operations47; 

- 

the  fourth  conference  of  ERNs48,  held  on  21-22 November 2018  in  Brussels,  organised  by  DG 

SANTE and Chafea.  

Activities associated with crisis preparedness included: 

-  publishing a specific e-booklet on health threats49; 

-  organising a conference in cooperation with the Greek Ministry of Health on 7-8 June 2018, ‘Best 

practices in implementing the International Health Regulations’50. 

Chafea also participated in five major public health conferences at European level where scientists and 

health professionals were the target audience. 

- 

- 

18th  International  Conference  on  Integrated  Care,  23-25 May 2018,  Utrecht,  the  Netherlands51, 
Health Programme workshops and stand. 
21st European Health Forum Gastein, 3-5 October 201852. 

-  European  Public  Health  Conference  2018,  28 November-1 December 2018,  Winds  of  change: 
towards new ways of improving public health in Europe53, health programme workshop, Ljubljana, 
Slovenia. 

-  49th Union World Conference on Lung Health, 24-27 October 201854, stand exhibition and ‘meet 

and greet’ sessions, The Hague, the Netherlands. 

46 https://ec.europa.eu/chafea/health/bookshelf/brochures/index_en.htm  
47 https://ec.europa.eu/chafea/health/bookshelf/infosheets/index_en.htm  
48 https://ec.europa.eu/health/sites/health/files/ern/docs/ev_20181121_ag_en.pdf    
49https://publications.europa.eu/en/publication-detail/-/publication/13b6f22d-75e4-11e8-ac6a-
01aa75ed71a1/language-
en?WT.mc_id=Selectedpublications&WT.ria_c=19980&WT.ria_f=3170&WT.ria_ev=search  
50 https://eody.gov.gr/en/event/best-practices-in-implementing-the-international-health-regulations/  
51 https://integratedcarefoundation.org/events/icic18-18th-international-conference-on-integrated-care-utrecht  
52 https://www.ehfg.org/archive/2018/conference  
53 https://ephconference.eu/conference-2018-Ljubljana-184  
54 https://thehague.worldlunghealth.org/  

37 

 
 
                                                      
-  AIDS  2018,  health  programme  workshops,  23-27 July 201855,  EU  stand  and  ‘meet  and  greet’ 
sessions,  Amsterdam,  the  Netherlands.  The  e-booklet  on  HIV/AIDS,  viral  hepatitis  and 
tuberculosis was produced and disseminated at the AIDS conference. 

Among  the  other  dissemination  actions,  the  medical  device  campaign56  on  the  new  EU  Regulations  on 

medical devices (MDR) and in vitro diagnostic medical devices (IVDR) was launched in 2018. Its purpose 

was to inform all parties involved, especially the manufacturers, about changes, new requirements and the 

timelines of the new regulations before their entry into force in 2020. 

In 2018, Chafea spent EUR 824 686 on dissemination activities, i.e. for organising events and covering the 

costs  of  venues  renting  space  for  stands  in  exhibitions,  travel  and  accommodation  of  experts,  and  the 

production and printing of materials. 

2.  Other actions  

2.1.  Sub-delegations to Eurostat, the statistical office of the European Union  

Background information 

Eurostat, the statistical office of the European Union, is the main source of comparable EU health data. Its 
mission is based on the framework regulation on health statistics57 and derived legal acts58.  

Brief description 

Eurostat provides two kinds of health statistics: administrative, such as statistics on the cause of death, and 

self-reported data from the European health interview survey or the minimum European health module of 

the EU-SILC survey. Themes covered by these statistics include: 

- 

- 

- 

- 

- 

- 

health status; 

health determinants; 

healthcare expenditure; 

healthcare resources and activities; 

causes of death; 

health and safety at work. 

55 https://www.aids2018.org/  
56 https://ec.europa.eu/growth/sectors/medical-devices_en  
57  Regulation  (EC)  No  1338/2008  of  the  European  Parliament  and  of  the  Council  of  16  December  2008  on 
Community statistics on public health and health and safety at work (OJ L 354, 31.12.2008, p. 70). 
58 https://ec.europa.eu/health/indicators_data/key_documents_en#anchor1  

38 

 
 
                                                      
Specific results 

The budget spent on all the activities under the support to Eurostat sub-delegations was EUR 987 580. This 

covered implementing the health information and knowledge system priorities to contribute to evidence-

based  decision-making,  including  supporting  the  scientific  committees  set  up  in  accordance  with 

Commission Decision 2008/721/EC. 

-  EUR 413 943 - testing new modules/variables for future waves of European health interview surveys.  

Through  this  action,  Eurostat  delivered  health  data  for  a  large  proportion  of  European  core  health 

indicators and other European health indicators, such as joint assessment framework health indicators.  

EU co-funding supported national adaptations, testing, and implementation of new variables/modules 

in  countries  that  want  to  integrate  them  on  a  voluntary  basis  in  the  2019  European  health  interview 

survey  for  preparing  possible  inclusion  in  future  waves  of  this  survey  in  all  Member  States.  The 
resulting  data  and  indicators  contribute  to  and  are  used  in  the  ‘State  of  Health  in  the  EU’59  cycle. 

Topics of interest included: 

  patient experience (taking OECD developments into account); 

  dietary habits, including sugar intake; 

  mental health-related issues; 

  disability and variables related to children’s health. 

-   EUR 527 575 - morbidity statistics.  

Pilot data collection on morbidity statistics supports the statistical authorities in the European statistical 

system in their efforts to provide data on morbidity and to develop the existing (or planned) sources 

and  methods  with  a  view  to  producing  best  national  estimates  for  the  indicators  included  in  the 

Eurostat  morbidity  indicators  shortlist.  EU  co-funding  was  used  to  run  pilot  data  collection  on 

diagnosis-based  morbidity  at  national level.  A  coordinated approach  by  Member  States to  morbidity 

statistics  is  required  to  ensure  data  comparability.  The  action  helped  to  develop  and  increase  the 

availability and comparability of data in 10 participating countries.  

-  EUR 46 062 non-monetary healthcare statistics.  

59 https://ec.europa.eu/health/state/summary_en  

39 

 
 
                                                      
The  action  on  non-monetary  healthcare  statistics  supports  the  statistical  authorities  in  the  European 

statistical system in their efforts to increase quality and coverage of non-monetary data on healthcare. 

The action also supports countries to advance their readiness to provide data under an implementing 

regulation.  EU  co-funding  supported  efforts  with  EU  added  value,  enabling  countries  to  report 

complete, high-quality data sets. This action contributes to the availability and comparability of data 

across  the  EU  and  provides  a  basis  for  policy-making  grounded  in  factual  evidence.  The  data  are 

validated and disseminated annually by Eurostat. 

More  information  about  EU  health  data  can  be  found  on  Eurostat’s  website60  and  on  DG  SANTE’s 

health indicators and data website61. 

2.2. What did the ERNs achieve in practice with the first year of SGA support? 

Background 

ERNs  are  virtual  networks  involving  healthcare  providers  across  Europe.  Their  purpose  is  to  tackle 

complex  or  rare  diseases  and  conditions  requiring  highly  specialised  treatment  and  a  concentration  of 

knowledge and resources. 

To  review  a  patient’s  diagnosis  and  treatment,  ERN  coordinators  convene  ‘virtual’  advisory  boards  of 

medical specialists across different disciplines, using a dedicated IT platform and telemedicine tools. ERNs 

offer the potential to give patients and doctors throughout the EU access to the best expertise and timely 

exchange of life-saving knowledge, without having to travel to another country.  

Following the first call for proposals in July 2016, the first ERNs were approved in December 2016 and 

launched  in  March  2017  in  Vilnius,  where  their  inaugural  meetings  were  held.  At  their  inception,  the 

networks  comprised  more  than  900  highly  specialised  healthcare  units  located  in  313  hospitals  in  25 

Member States (plus Norway). 

The budget earmarked for the ERNs under specific objective 4.1 priority - European reference networks in 

2018 was as follows: 

  EUR 13 691 043.13 on SGAs for 23 ERNs; 

  EUR 4 000 000 on activities related to capacity building, communication, exchange of information 

and best practices, and other networking support actions. 

60 https://ec.europa.eu/eurostat/web/health/overview  
61 https://ec.europa.eu/health/indicators_data/overview_en 

40 

 
 
                                                      
Brief description 

In the first year of their specific grants, the ERNs laid the groundwork for the key strategic activities by 

building their operational framework and setting up all the necessary support and coordination services for 

full operational capacity. The first-year grants enabled them to achieve the following specific objectives:  

1. 

improving the provision of high-quality and homogeneous specialised care to European patients by 

developing and promoting standard recommendations for better diagnosis and treatment; 

2. 

improving  physicians’  activity  and  patients’  empowerment  by  developing  the  necessary 

personalised IT services, such as e-health and e-learning tools; 

3. 

improving  medical  knowledge  by  sharing  experience  and  through  interaction  between  European 

healthcare  providers;  by  developing  and  conducting  training  courses  and  activities  for  both 

physicians and patients; 

4.  facilitating epidemiological, clinical and translational research by developing a standard approach 

for the collection of patients’ data and the creation of registries. 

Specific results  

The  ERNs  have  established  their  governance  models,  including  advisory  boards,  steering  committees  or 

other  means  of  involving  stakeholders  (e.g.  patient  representatives).  Several  ERNs  have  established  or 

further developed databases or registries, including quality assurance schemes for diagnostics. Others have 

focused on learning and development activities, e.g. surveys to identify educational gaps, e-learning and e-

training tools, and twinning programmes. Capacity building has been improved by holding workshops and 

producing webinars, while several ERNs have also focused their work in order to identify e-health and ICT 
and research gaps. A clinical patient management system62 has been set up by the Commission, and ERN 
consultations were carried out through the system63. 

Transversal  cooperation  among  ERNs  was  ensured  through  dedicated  working  groups  on  (a).  education, 

clinical  guidelines  and  recommendations,  (b).  registries  and  bio  banks,  (c).molecular  testing,  IT  and  e-

health,  stem  cell  and  gene  therapies,  (d).  pharmacovigilance  and  biological  therapies,  transition  care, 

research, patient organisations and communication. 

62 https://ec.europa.eu/health/sites/health/files/ern/docs/ev_20181121_frep_en.pdf  
63  CMPS  is  a  web-based  clinical  software  application  allowing  healthcare  providers  from  all  over  the  EU  to  work 
together virtually to diagnose and treat patients with rare, low-prevalence and complex diseases. 

41 

 
 
                                                      
For more on ERNs, see DG SANTE’s website64and Chafea’s Health Programme database65. 

64 http://ec.europa.eu/health/ern/networks_en 
65 https://webgate.ec.europa.eu/chafea_pdb/health  

42 

 
 
 
 
                                                      
IMPLEMENTATION OF THE ANNUAL WORK PROGRAMME FOR 2018  

CALLS FOR PROPOSALS 

Between January 2018 and January 2019 Chafea launched calls for proposals for projects, and invitations 

to  submit  proposals  for  JAs,  for  specific  grants  for  ERNs,  and  operating  grants  for  NGOs  on  the  single 
electronic data interchange area for funding and tender opportunities66.  

Four calls for proposals for projects were published. Two of these were for health promotion, prevention 

and integrated care for non-communicable diseases, including transferring and/or scaling up existing good 

and best practices. The other two had to do with supporting voluntary cooperation between EU countries 

on  national  policies  for  the  pricing  of  medicinal  products  and  improving  information-gathering  on  rare 

diseases through the implementation of Orphacodes. 

All  applications  for  ERN-specific  grants  in  2018  and  FPA/SGA  for  operating  grants  to  NGOs  were 
submitted  by  organisations  in  the  EU-1567,  apart  from  one  FPA/SGA  signed  with  an  EU  umbrella 

organisation from Cyprus.  

The  JA  designed  to  improve  EU  preparedness  for  serious  cross-border  health  threats  and  to  support  the 

implementation  of  the  international  health  regulationsknown  as  SHARP,  brought  together  26  countries. 

Thirteen  beneficiaries  were  organisations  from  EU-15  countries,  nine  were  from  EU-12  (countries  that 

joined  the  EU  after  2004)  and  four  other  partners  were  non-EU  countries  (EEA,  and  European 

neighbourhood policy (ENP) countries).  

Looking  at  the  geographical  distribution  of  the  211  grant  beneficiaries,  156  (74%)  are  from  an  EU-15 

country, 46 (22%) from EU-12 countries, four from Norway or Iceland (2%) and five from ENP countries 

(Bosnia Herzegovina, Serbia and Moldova) (2%). 

Graphic 4: Participation in health programme grants (%)  

66https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-
search;freeTextSearchKeyword=;typeCodes=1;statusCodes=31094501,31094502,31094503;programCode=3HP;prog
ramDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=Default;sortQuery=openingDa
te;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState  
67 EU-15 countries (Belgium (BE), Denmark (DK), France (FR), Germany (DE), Greece (EL), Ireland (IE), Italy (IT), 
Luxembourg (LU), the Netherlands (NL), Portugal (PT), Spain (ES), United Kingdom (UK), Austria (AT), Finland 
(FI) and Sweden (SE), https://ec.europa.eu/eurostat/statistics-explained/index.php/Glossary:EU_enlargements  

43 

 
 
                                                      
EEA 
2% 

ENP 
2% 

EU 12 
22% 

EU 15  
74% 

Chafea  organised  two  webinars  as  information  days  to  promote  the  2018  AWP:  the  first,  presenting 

funding  opportunities  and  held  on  30 January 2018,  attracted  154  participants.  The  second,  held  on 

2 February 2018,  drew  55  participants;  it  was  restricted  to  competent  authorities  of  the  countries 

participating  in  the  programme  and  presented  the  JA  nomination  process  and  the  policy  priorities.  This 

initial information session was followed by a JA 2018 preparatory workshop held on 16 June 2018 and by 

the quality assurance workshop on 11 October 2018.  

To promote participation in the 2018 calls, the national focal points68 for the health programme held eight 
national information days69 from February to March 2018 in five EU countries and three in other countries 

participating in the health programme. Chafea made guidelines for applicants available on the participant 

portal. The Chafea helpdesk also provided assistance and practical help. 

Expert evaluators 

Applications were evaluated in accordance with the rules and criteria set out in the 2018 AWP and in the 

specific calls for proposals.  

The  proposals  submitted  under  different  calls  for  proposals  were  evaluated  by  external  experts  (peer 

reviewers)  drawn  from  a  list  established  after  the  call  for  expressions  of  interest  in  the  area  of  public 

68 http://ec.europa.eu/chafea/health/national-focal-points/index_en.htm  
69 https://ec.europa.eu/chafea/health/national-info-days/2018-nid_en.htm  

44 

 
 
 
                                                      
health – EMI H2020 database70. The external evaluation of the call for proposals supports the efficient and 

transparent selection of proposals funded under the 2018 AWP. 

17  external  experts  from  12  countries  took  part  in  the  evaluation  process  for  the  award  of  the  operating 

grants, projects and ERN grants and assessed the JA during the quality assurance workshop. 

The evaluation process took place in two stages: 

  At the first stage, three external evaluators assessed each proposal. They drew up a consolidated 

evaluation report for each proposal at the consensus meeting organised by Chafea.  

  At the second stage, the evaluation committee reviewed the work of the external evaluators and 

drew up the final lists of proposals recommended for funding, together with the reserve lists. The 

evaluation  committee  comprised  representatives  from  DG  SANTE,  the  Directorate-General  for 

Research and Innovation, and Chafea.  

Project grants 

Project grants were awarded to actions involving 105 organisations, mainly public health bodies, research 

institutions  and  NGOs.  The  maximum  EU  contribution  is  60%  of  eligible  costs.  However,  the  EU 

contribution  may  go  up  to  80%  if  a  proposal  meets  the  criteria  for  ‘exceptional  utility’  indicated  in  the 

AWP.  

Chafea launched the first call for proposals for projects in January 2018, in the following areas: 

  A call for projects on scaling up integrated care: nine proposals were submitted, two of which were 

funded. 

  Supporting  Member  States’  voluntary  cooperation  in  the  area  of  pricing  through  EURIPID 

cooperation: one proposal was funded. 

  The Orphacodes project: one proposal was funded. 

Two  calls  for  projects  were  launched  in  June  2018  to  support  the  implementation  of  best  practices  to 

promote health and prevention of non-communicable diseases and reduce health inequalities as part of the 

work of the steering group on health promotion, disease prevention and management of non-communicable 

diseases (SGPP):  

  Transferring  the  Swedish  ‘physical  activity  on  prescription’  initiative  to  other  countries:  one 

proposal was submitted and funded. 

70 EMI - https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/work-as-an-expert  

45 

 
 
                                                      
  Transferring the Italian CARDIO 50 programme to other countries: two proposals were submitted, 

one of which was funded.   

A third call for projects to transfer the Wholegrain promotion initiative to other countries was launched in 

December 2008. One proposal was received and funded. 

In all, 15 proposals were submitted in response to the 3 calls for proposals for projects. One proposal was 

ineligible, 14 proposals were evaluated and 9 proposals reached the threshold values.  

In 2018, seven projects were funded for the six topics of the calls for proposals.  

46 

 
 
 
 
The table below lists the project grants funded by objective and priority.  

Instrument 
Objectives 
Description of 
objectives 
Thematic priority 

User reference 

Project grants by objective 
1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles 
1.4. Chronic diseases including cancer, age-related 
diseases and neurodegenerative diseases  
Title 

847130 

847174 

874482 

826640 

826676 

TOTAL 
Objectives 
Description of 
objectives 
Thematic priority 

User reference 

826652 

TOTAL 

YOUNG50 #Stay Healthy - Cardiovascular Risk 
Prevention 
EUPAP – A European Physical Activity on 
Prescription model 
WholEUGrain – A European Action on Whole Grain 
Partnerships 
Evidence-Based Guidance to Scale Up Integrated 
Care in Europe 
Personalised knowledge transfer and access to 
tailored evidence-based assets on Integrated Care: 
SCIROCCO exchange 

3 
3. Contribute to innovative, efficient and sustainable 
health systems 
3.4. Setting up a mechanism for pooling expertise at 
Union level 
Title 

Supporting Member States’ voluntary cooperation in 
the area of pricing through EURIPID 

Objectives 

4 

Description of 
objectives 
Thematic priority 
User reference 

4. Facilitate access to better and safer healthcare for 
Union citizens 
4.1. European reference networks 
Title 

826607 
TOTAL 
TOTAL PROJECTS 

Codification for Rare Diseases 

Amount committed in 
EUR 

983 255.00 

1 346 154.90 

1 140 448.00 

1 827 608.14 

1 508 988.09 

6 806 454.13 

Amount committed in 
EUR 
299 994.00 

299 994.00 

Amount committed in 
EUR 
749 884.35 
749 884.35 
7 856 332.48 

47 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
European reference networks (mono-beneficiary grants) 

In  2017,  23  ERNs  submitted  an  FPA  proposal,  together  with  their  SGA  proposals  for  the  first  year  of 

operation of the ERNs. In 2018, Chafea awarded 23 SGAs covering three years (2019-2021). 

There were two waves of ERN SGA 2018 grant preparation. Initially, 18 ERNs were sent an invitation to 

submit  their  annual  work  programme  for  funding.  A  second  wave  of  invitations  was  sent  after  an 

amendment had been adopted on the five ERNs with UK-based coordinators.  

Under the financing decision, each network could receive up to EUR 200 000 annually. However, not all 

networks requested the full amount available. The co-funding awarded to each ERN is set out below. 

EU funding for three-year SGA grants for ERNs totalled EUR 13 691 043.13. 

Financial instrument 

ERN SGAs by objective 

Objectives 
Description of objectives 

4 
4. Facilitate access to better and safer healthcare for 
Union citizens 

Thematic priority 

4.1. Support the establishment of a system of 
European reference networks for patients with 
conditions requiring highly specialised care 

User reference 

Title 

844802- ERN-RND - 
ERN-SGA-2018 

European Reference Network for Rare 
Neurological Diseases 

Amount 
committed in 
EUR 

600 000.00 

847032- ERN-
PAEDCAN - ERN-
SGA-2018 
845755- ERKNet - 
ERN-SGA-2018 

European Reference Network on Paediatric Cancer 
Y3-5  

600 000.00 

European Rare Kidney Disease Reference Network 

597 824.00 

870177- ERN-NMD– 
Y2 - ERN-SGA-2018 

European Reference Network for Rare 
Neuromuscular Diseases  

844879- ERN 
GENTURIS - ERN-
SGA-2018 
838437- ERN-SKIN - 
ERN-SGA-2018 

844295- ERN- GUARD 
HEART - ERN-SGA-
2018 

European Reference Network on Genetic Tumour 
Risk Syndromes 

European Reference Network on Rare and 
Undiagnosed Skin Disorders - Year 3 to 5 

European Reference Network for Rare and Low-
Prevalence Complex Diseases of the Heart 

600 000.00 

596 168.00 

600 000.00 

569 935.00 

48 

 
 
 
 
 
 
847115- ERN-
RECONNET - ERN-
SGA-2018 

European Reference Network on Rare and 
Complex Connective Tissue and Musculoskeletal 
Diseases  

599 981.00 

European Reference Network for  Rare Adult Solid 
Cancers, 2019-2022 

599 307.00 

842449- ERN-
EURACAN 3-5 - ERN-
SGA-2018 
846451- Endo-ERN - 
ERN-SGA-2018 

European Reference Network on Rare Endocrine 
Conditions 

847081- VASCERN - 
ERN-SGA-2018 

European Reference Network on Rare 
Multisystemic Vascular Diseases - 3 years 

843704- ERN-LUNG - 
ERN-SGA-2018 

European Reference Network on Rare Respiratory 
Diseases 

847078- ERN BOND - 
ERN-SGA-2018 

European Reference Network on Rare Bone 
Diseases - years 3 to 5 

869189- ERN-ITHACA 
- ERN-SGA-2018 

European Reference Network on Congenital 
Malformations and Rare Intellectual Disability 

847091- MetabERN - 
ERN-SGA-2018 

European Reference Network on Hereditary 
Metabolic Disorders – 3-year plan 

869229- ERN-RARE 
LIVER - ERN-SGA-
2018 
870280- EpiCARE - 
ERN-SGA-2018 

870267- ERN RITA -
ERN-SGA-2018 

844980- ERN-EYE - 
ERN-SGA-2018 

847140- ERN-
EuroBloodNet - ERN-
SGA-2018 

European Reference Network on Hepatological 
Diseases 

European Reference Network for Rare and 
Complex Epilepsies 

European Reference Network on Rare 
Immunodeficiencies, Autoinflammatory Disorders 
and Autoimmune Diseases: Year 3-5 WP 
European Reference Network on Rare Eye 
Diseases, 2019-2021 

European Reference Network on Rare 
Haematological Diseases 

847176- ERN CRANIO 
- ERN-SGA-2018 

European Reference Network on Rare Craniofacial 
Anomalies and ENT Disorders 

847139- ERNICA - 
ERN-SGA-2018 

European Reference Network for Rare Inherited 
and Congenital Anomalies 

European Reference Network for Transplantation 
in Children 

847103- ERN- 
TRANSPLANTChild - 
ERN-SGA-2018 

TOTAL ERN SGAs 

Operating grants 

600 000.00 

599 999.00 

589 163.00 

600 000.00 

544 806.00 

595 134.00 

599 987.00 

600 000.00 

599 529.13 

599 972.00 

599 238.00 

600 000.00 

600 000.00 

600 000.00 

13 691 043.13 

Operating  grants  are  awarded  to  non-governmental  bodies  that  pursue  one  or  more  of  the  health 

programme’s specific objectives and 

49 

 
 
  
 
 

 

are non-governmental; 

are non-profit-making and independent of industry, commercial and business or other conflicting 

interests; 

  work in public health; 

  play an effective role in civil dialogue processes at EU level; 

  pursue at least one of the programme’s specific objectives; 

 

active at EU level and in at least half of Member States; and 

  have a balanced geographical coverage of the EU. 

All activities covered by Annex 1 to the Regulation establishing the third health programme can be funded 

by a specific grant awarded under an FPA for the functioning of non-government bodies (operating grants).  

Sixteen EU umbrella organisations signed an FPA in 2017, covering 2018-2021 and focusing on, though 

not limited to, the following priority areas: prevention and health determinants, chronic diseases, cancer, 

dementia,  rare  diseases,  HIV/AIDS,  tuberculosis,  hepatitis,  access  to  healthcare,  substances  of  human 

origin. 

FPA recipients are eligible for an SGA for their operations. In 2018, FPA recipients were asked to apply 

for an SGA to cover their operating costs for 2019. The maximum EU contribution is 60% of their annual 

operating costs, but may rise to 80% if a proposal meets the criteria for exceptional utility.  

In 2018, six of the 16 operating grants signed, 37.5%71, met the exceptional utility conditions.  

At  the  end  of  2018,  the  grant  preparation  process  was  completed,  representing  a  volume  of 

EUR 5 887 958.53. 

The table lists all operating grants funded by objective and priority. 

Financial 
instrument 
Objectives 
Description of 
objectives 

Operating grants by objective 

1 
1. Promote health, prevent diseases and 
foster supportive environments for 
healthy lifestyles 

Thematic priority 

1.1. Cost-effective promotion and 
prevention measures in line, in particular, 
with the Union strategies on alcohol and 

71 Operating grants, SGA 2018 with EU funding higher than 60%: smoke-free partnership, correlation network, AIDS 
action  Europe,  European  network  for  smoking  and  tobacco  prevention,  European  public  health  alliance,  and 
Thalassaemia in action. 

50 

 
 
 
 
 
 
                                                      
nutrition 

User reference 

Title 

Amount committed in 
EUR 

836149- OBTAINS-
E2 - SGA-2018 

Obesity Training and Information 
Services in Europe phase 2 

837244- EUPHA 
SGA-2018  

European Public Health Association 
(EUPHA) 2018 

837741 - SFP SGA 
2018  

837742 -EHN SGA 
2018- 

836452 - ENSP FY 
2019 - SGA-2018 

837500 – EPHA 
2019 - SGA-2018 

Preventing cancer and chronic diseases 
through smoking prevention - 2019 
annual work programme for the Smoke-
Free Partnership 
European Heart Network - Cardiovascular 
Health at the Heart of EU Policies 

European Network for Smoking and 
Tobacco Prevention – Paving the way for 
a tobacco-free Europe 
European Public Health Alliance (EPHA 
SGA 2019) 

837860 – SHE 2019 
- SGA-2018 

Schools for Health in Europe Network 
Foundation 

Total 
Thematic priority 

User reference 

835781- TBEC - 
SGA-2018 
836479- AAE - 
SGA-2018 
836307-CN- SGA-
2018 
Total 
Thematic priority 

User reference 

832650 - AE2019 - 
SGA-2018 
837880 - ECL SGA 
2019  
Total 
Objectives 
Description of 
objectives 

1.3. Support effective responses to 
communicable diseases such as 
HIV/AIDS, tuberculosis and hepatitis 
Title 

TBEC: strengthening TB response in the 
WHO Europe region 
AIDS Action Europe - Stronger Together 

Correlation - European Harm Reduction 
Network 

1.4. Support cooperation and networking 
in the Union in relation to preventing and 
improving the response to chronic 
diseases 
Title 

Alzheimer Europe 2019 

European Cancer Leagues -Collaborating 
for Impact in Cancer Control (2019) 

3 
3. Contribute to innovative, efficient and 
sustainable health systems 

51 

223 710.00 

300 539.00 

474 467.73 

394 738.80 

394 128.00 

554 996.00 

356 020.00 

2 698 599.53 

Amount committed in 
EUR 

123 282.00 

316 051.00 

201 375.00 

 640 708.00 

Amount committed in 
EUR 

459 324.00 

310 355.00 

769 679.00 

 
 
  
 
  
 
  
 
 
Thematic priority 

User reference 

3.6. Implementation of Union legislation 
in the field of medical devices, medicinal 
products and cross-border healthcare 
Title 

836477 - HAI2019 - 
SGA-2018 

A Plan for Action: Ensuring Equitable, 
Affordable and Responsibly Used 
Medicines in the European Union 

4 
4. Facilitate access to better and safer 
healthcare for Union citizens 
4.2. Coordinated action at Union level in 
order to effectively help patients affected 
by rare diseases 
Title 

Eurordis Rare Diseases Europe SGA 
2019 

Amount committed in 
EUR 

250 000.00 

250 000.00 

Amount committed in 
EUR 

1 029 456.00 

Thalassaemia in Action 2019 

251 795.00 

4.5. Implementation of Union legislation 
in the fields of human tissues and cells, 
blood, human organs, medical devices, 
medicinal products, and patients’ rights in 
cross-border healthcare 
Title 

High-quality blood stem cell products for 
all patients in need, while protecting 
voluntary donors’ rights and welfare 

1 281 251.00  

Amount committed in 
EUR 

247 721.00 

247 721.00 
5 887 958.53 

Total 
Objectives 
Description of 
objectives 
Thematic priority 

User reference 

838112 - 
EURORDIS SGA 
2019 - SGA-2018 
838053 – THALIA 
SGA 2019 - SGA-
2018 
Total 
Thematic priority 

User reference 

837354 - SAVDON 
- SGA-2018 

Total 
Chafea TOTAL 
OPERATING 
GRANTS 

JOINT ACTIONS 

The grants for actions co-financed with Member State authorities are ‘actions having a clear Union added 

value co-financed by the competent authorities that are responsible for health in the Member States or in 

third countries participating in the Programme pursuant to Article 6, or by public sector bodies and non-

52 

 
 
 
 
 
 
 
 
  
 
  
  
 
governmental bodies, as referred to in Article 8(1), acting individually or as a network, mandated by those 
competent authorities72’. 

They thus enable the nominated national authorities of the Member States and other countries participating 

in the programme, and the Commission, to take forward work on jointly identified issues.  

The maximum EU contribution is 60%, but may rise to 80% if a proposal meets the criteria for exceptional 

utility.  

Countries participating in the third health programme nominate the competent authorities or other bodies, 

which are asked to submit a proposal under the direct grant procedure. 

In 2018, co-funding totalling EUR 7 900 000.00 was provided to a JA addressing objective 2 of the health 

programme, ‘Protect Union citizens from serious cross-border health threats’. This was because it qualified 

as exceptional utility. 

The  SHARP  JA  brings  together  26  associated  partners,  33  affiliated  entities,  and  9  collaborating 

stakeholders, in a total of 30 countries (24 EU countries, three EEA/EFTA members, and three European 

neighbourhood countries). 

The table below lists the joint actions funded by objective and priority.  

Financial instrument  Joint actions by objective 
2 
Objectives 
2. Protect Union citizens from serious cross-border 
Description of 
health threats 
objectives 
2.2. Capacity building against health threats in 
Thematic priority 
Member States, including, where appropriate, 
cooperation with neighbouring countries 
Title 

User reference 

848096- SHARP - 
HP-JA-2018 
Chafea TOTAL 
JOINT ACTION 

Strengthened International Health Regulations and 
Preparedness in the EU - Joint Action 

Amount committed in 
EUR 
7 900 000.00 

7 900 000.00 

DIRECT GRANT AGREEMENTS AND PRESIDENCY CONFERENCES 

Direct grant agreements are awarded to international organisations active in the area of public health ‘for 

activities  with  specific  characteristics  that  require  a  particular  type  of  body  on  account  of  its  technical 

72  Definition  of  joint  actions  in  Article  7.2(a)  of  the  Regulation  for  the  third  Health  Programme  2014-2020, 
https://ec.europa.eu/health/funding/programme_en  

53 

 
 
 
 
 
 
 
 
                                                      
competence, its high degree of specialisation or its administrative powers, on condition that the activities 
concerned do not fall within the scope of a call for proposals73’.  

Funding  for  actions  with  international  organisations  will  be  allocated  exclusively  through  grant 

agreements,  without  a  call  for  proposals  on  topics  specifically  identified  in  the  work  programme.  The 

maximum EU contribution is 60%. 

In 2018, five direct grant agreements were signed by Chafea, covering a total of EUR 4 020 000, with the 
WHO, the OECD and the Council of Europe. 

The table below lists all direct grant agreements funded by objective and priority. 

Financial 
instrument 
Objectives 
Description of 
objectives 

Direct grant agreements by objective 

1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles 

Thematic priority 

1.5. Implementation of Union legislation in the field of 
tobacco products 

User reference 

Title 

Amount committed in 
EUR 

 20185102 

 WHO Framework Convention on Tobacco Control 

720 000.00 

Total 
Objectives 
Description of 
objectives 
Thematic priority 

User reference 

20185201 
Total 
Thematic priority 

User reference 

20185401 

Total 
Objectives 
Description of 
objectives 
Thematic priority 

3 
3. Contribute to innovative, efficient and sustainable 
health systems 
3.2. Promote the voluntary uptake of health innovation 
and e-Health 
Title 

Best practices & Digital Strategy (OECD) 

3.7. Foster a health information and knowledge system 
to contribute to evidence-based decision-making 
Title 

Support to implementation of national action plans on 
Antimicrobial Resistance (AMR) OECD 

4 
4. Facilitate access to better and safer healthcare for 
Union citizens 
4.3.  Strengthen  cooperation  on  patient  safety  and 

720 000.00 

Amount committed in 
EUR 
750 000.00 
750 000.00 

Amount committed in 
EUR 
600 000.00 

600 000.00 

73 Article 195(f) of Regulation (EU, Euratom) 2018/1046. 

54 

 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
                                                      
quality of healthcare  
Title 

Develop patient-reported measures (OECD) 

4.5. Implementation of Union legislation in the fields of 
human tissues and cells, blood, human organs, medical 
devices, medicinal products and patients’ rights in 
cross-border healthcare 
Title 

European Pharmacopoeia (EDQM) (Council of Europe) 

Amount committed in 
EUR 
450 000.00 
450 000.00 

Amount committed in 
EUR 
1 500 000.00 
 1 500 000.00 
4 020 000.00 

User reference 

20185302 
Total 
Thematic priority 

User reference 

 20185301  
Total 
TOTAL DIRECT 
GRANTS 

Other direct grants 

The table below lists other direct grants funded by objective and priority.  

Financial instrument  Direct grants by objective 
4 
Objectives 

Description of 
objectives 
Thematic priority 

User reference 

4. Facilitate access to better and safer healthcare for 
Union citizens 
4.2. Support Member States, patient organisations and 
stakeholders by coordinated action at Union level in 
order to effectively help patients affected by rare 
diseases 
Title 

831386 

ERN eUROGEN network 

831390 
TOTAL Other 
Direct grants 

Orphanet network 

Amount committed in 
EUR 
600 000.00 

2 639 462.53 
3 239 462.53 

Presidency conferences 

The  Presidency  conferences  financed  under  the  2018  AWP  were  the  ones  held  under  the  Austrian  and 

Romanian EU Presidencies.  

The  conference  on  ‘People's  food,  people's  health:  towards  healthy  and  sustainable  European  food 
systems’74  was  held  on  22-23 November 2018  in  Vienna.  It  facilitated  dialogue  between  all  relevant 

74 https://www.eu2018.at/calendar-events/political-events/BMASGK-2018-11-22-EU-Food-Systems.html 

55 

 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
                                                      
stakeholders  in  the  food  sector  on  moving  towards  a healthier and  more  equitable  future.  A  healthy  and 

sustainable diet must become available, affordable, acceptable and appealing to all. 

Under  the  Romanian  Presidency,  the  ministerial  conference  ‘Next  steps  towards  making  the  EU  a  best 
practice  region  in  combating  antimicrobial  resistance  through  a  One  Health  approach’75  was  held  in 

Bucharest  on  1 March 2019.  The  key  content  of  the  Council  conclusions  on  AMR  was  adopted  in  June 

2019. 

Financial instrument  Health programme support to Presidency conferences 

Objectives 
Description of 
objectives 

Thematic priority 

by objective 
1 
1. Promote health, prevent diseases and foster supportive 
environments for healthy lifestyles 

1.1. Cost-effective promotion and prevention measures in 
line, in particular, with the Union strategies on alcohol and 
nutrition 

User reference 

Title 

HP-PC-FOODSYS 

People's food - people's health: towards healthy and 
sustainable European Food Systems 

Objectives 

4 

Description 
objectives 

of 

4. Facilitate access to better and safer healthcare for Union 
citizens 

Thematic priority 

4.4. Measures to prevent antimicrobial resistance and 
control healthcare-associated infections 

User reference 

Title 

Next steps towards making the EU a best practice region 
in combating AMR through a One Health approach 

HP-AMR-PC 

Chafea TOTAL 
PRESIDENCY 
CONFERENCES 

Amount 
committed in EUR 

100 000.00 

Amount 
committed in EUR 

66 000.00 

    166 000.00 

PRIZES – EU health award for NGOs 

In 2018, the Commission rewarded outstanding initiatives by NGOs that contributed to a  higher level of 

public health in the EU by working to prevent tobacco use. Eleven candidate NGOs were considered for 

the prize. The Commission announced the winners on 12 November 2018 at the award ceremony hosted at 

75 http://www.ms.ro/wp-content/uploads/2019/01/Outcomes-document-PRES-RO-AMR-conference.pdf 

56 

 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
                                                      
the annual meeting of the EU Health Policy Platform, in the presence of the EU Commissioner for Health 
and Food Safety, Vytenis Andriukaitis76. 

Financial instrument 

PRIZES – EU health award for NGOs  

Objectives 
Description of objectives 

1-4 
All Programme objectives 

Thematic priority 

N/A (EU Health award for NGOs) 

User reference 

Title 

C4 - SI2.777187 - 17.030100  

EU health award for NGOs 

C4 - SI2.777187 - 17.030100  

 EU health award for NGOs 

Chafea TOTAL PRIZES 

PROCUREMENTS (SERVICE CONTRACTS) 

Amount committed in 
EUR 

45 000.00  

15 000.00  

60 000.00  

Procurement  service  contracts  were  used  to  purchase  different  types  of  services.  Unlike  the  grants,  the 

health programme covers the full cost of the procurement actions for the following tasks: 

 

 

evaluation, monitoring of actions and policies, including impact assessment; 

studies, data analysis and information on health; 

  developing and maintaining databases; 

  organising workshops, courses, expert panels and coordination groups; 

 

 

 

 

scientific and technical assistance, provision of advice and opinions; 

communication, translations and publications; 

awareness raising and dissemination of the results; and 

information technology applications in support of policies. 

In  2018,  DG  SANTE  signed  several  service  contracts  and  specific  requests  using  existing  framework 

contracts  (FWC).  Most  of  these  contracts  and  requests  were  for  cross-cutting  actions  such  as 

communication and IT services for the maintenance and functioning of existing IT tools. 

Procurement  contracts  also  included  contracts  with  experts  working  for  the  scientific  committees, 

evaluating proposals and monitoring studies.  

76 2018 Working to prevent tobacco use, 
https://ec.europa.eu/health/ngo_award/previous_editions/2018/preventing_tobacco_use_en  

57 

 
 
 
 
 
 
  
  
 
 
 
 
 
  
 
                                                      
The amounts by objective and authorising organisation were as follows: 

Health programme 

Procurement managed by DG 

Procurement managed by 

objective 

SANTE (EUR) 

1. Health promotion 

2. Health threats 

 0.00 

0.00 

Chafea (EUR) 

1 840 980.00 

0.00 

3. Health systems 

2 740 000.00 

531 000.00 

4. Better and safer healthcare 

4 229 892.82 

0.00 

systems 

Cross-cutting actions 

3 404 049.55 

TOTAL 

10 373 942.37 

246 032.85 

2 618 012.85 

The overall public procurement budget implemented by DG SANTE amounted to EUR 10 373 942.37. 

The overall public procurement budget implemented by Chafea amounted to EUR 2 618 012.85.  

In  2018,  Chafea  managed  nine  procurement  procedures  for  the  acquisition  of  services  –  seven  under 

‘health  promotion’,  one  under  ‘health  systems’,  none  under  ‘health  threats  and  objectives  for  better  and 

safer  healthcare’  and  one    cross-cutting  contract  supporting  the  dissemination  of  the  health  programme 

results.  

The table below lists, by objective and priority, all contracts signed by Chafea and by DG SANTE. 

Financial instrument 
Objectives 
Description of objectives 

Chafea service contracts by objective 
1 
1. Promote health, prevent diseases and foster 
supportive environments for healthy lifestyles 

Thematic priority 

1.1. Cost-effective promotion and prevention 
measures in line, in particular, with the Union 
strategies on alcohol and nutrition 

User reference 

Title 

20187106 

Total 
Thematic priority 

User reference 

Support to Member States in reducing alcohol-
related harm (FAR SEAS) 

1.5. Implementation of Union legislation in the 
field of tobacco products 
Title 

20187401 

Provision of technical and scientific input to 

58 

Amount  committed  in 
EUR 

999 350.00 

999 350.00 

Amount  committed  in 
EUR 

239 830.00 

 
 
 
 
 
 
 
 
  
 
20187101 

20187102 
20187103 
20187104 
20187105 
Total 
Objectives 
Description of objectives 

Thematic priority 

User reference 

20187301 

support the application, enforcement and 
monitoring of the Tobacco Products Directive 
2014/40/EU  
Establishing a baseline/reference group for 
product testing 
Sensory assessors 
Product testing 
Methodology specification 
Initial training 

3 
3. Contribute to innovative, efficient and 
sustainable health systems 
3.6. Implementation of Union legislation in the 
field of medical devices, medicinal products and 
cross-border healthcare 
Title 

Information and communication campaign on 
the new Regulations on medical devices, module 
2 and 3 

Total 
Cross-cutting actions related to all objectives (IT/dissemination) 
User reference 

Title 

SC 2018 102 01 

Total 
Chafea TOTAL 
SERVICE CONTRACTS 

Five events and the Health Programme stand 
exhibition 

Financial 
instrument 
Objectives 
Description of 
objectives 
Thematic priority 

User reference 

SANTE service contracts by objective 

3 
3. Contribute to innovative, efficient and sustainable 
health systems 
3.4. Setting up a mechanism for pooling expertise at 
Union level  
Title 

B1 - 17030100 - SC 
No 114  

ORGANISATION OF 3 HEARINGS OF EXPERT 
PANEL ON EFFECTIVE WAYS IN INVESTING IN 
HEALTH - PROPAGER 

Total 

Thematic priority 

User reference 

3.6. Implementation of Union legislation in the field of 
medical devices, medicinal products and cross-border 
healthcare 
Title 

59 

77 000.00 

60 800.00 
303 000.00 
64 000.00 
97 000.00 
841 630.00 

Amount  committed  in 
EUR 

531 000.00 

531 000.00 

Amount committed in 
EUR 

246 032.85 

246 032.85 
2 618 012.85 

Amount committed 
in EUR 

37 400.00 

37 400.00 

Amount committed 
in EUR 

 
 
  
 
 
 
 
  
 
 
 
  
  
 
 
 
 
 
 
  
 
 
GROW/D4 - MEETINGS OF THE MEDICAL 
DEVICES COORDINATION GROUP (MDCG) 
COVERING TRAVEL EXPENSES OF 
PARTICIPANTS - 2018 
GROW.R.3 - E-ORDER 2018-13347 - OF 5167 - CC 
DI/7360 - COMPAREX - SPARX SYSTEMS 
ENTERPRISE ARCHITECT CORPORATE 
FLOATING EDITION - NEW LICENSES 
GROW.R.3 - E-ORDER 2018-16042 - OF 5223 - CC 
DI/7360 - COMPAREX (NL) - JETBRAINS 
INTELLIJ IDEA NEW LICENSES  
GROW.R.3 - SI2.794578 - OF 1002489 - CC DI/7720 
- BECHTLE(BE) - TOAD DATE MODELLER  
CS 14122 - CC DI/7330 - EURORA-1-ARHS (LU) - 
E-ORDER 2018-10613 - MIHNEA ANDREI 
MAGHETI - APPLICATION 
ARCHITECT/DESIGNER LEVEL 3 
GROW.R.3 - CS 1963 - CC DI/7390 - SINCRONIT-
SERCO (BE) - E-ORDER 2018-12033 - GIUSEPPE 
PERRICONE - SYSTEM ADMINISTRATOR 
LEVEL 5  
GROW.R.3 - CS 14368 - CC DI/7335 - INNOVATIA-
FUJITSU (BE) - E-ORDER 2018-12304 - NINA 
GEORGIEVA - BUSINESS ANALYST LEVEL 3  
GROW.R.3 - E-ORDER 2018-15200 - CS 14721 - CC 
DI/7331 - REMO MORO - PANOPLYS-
TRASYS(BE) - APPLICATION 
ARCHITECT/DESIGNER LEVEL 3 
GROW.R.3 - CS 14719 - CC DI/7337 - EURORA-2-
ORDINA(BE) - E-ORDER 2018-16790 - EZEKIEL 
FATUROTI - QUALITY CONSULTANT LEVEL 4 
GROW.R.3 - CS 14724 - CC DI/7335 - INNOVATIA-
TRASYS (BE) - E-ORDER 2018-17145 - MIKHAIL 
SAITAS - BUSINESS ANALYST LEVEL 5 
GROW.R.3 - SLG.CMM.2018.22010 - CS 15201 - CC 
DI/7331 - PANOPLYS-TRASYS (BE) - E-ORDER 
2018-22010 - ASHLEY COUPLAND - 
APPLICATION ARCHITECT/DESIGNER LEVEL 4 
GROW.R.3 - SLG.CMM.2018.23107 - CS 15202 - CC 
DI/7335 - INNOVATIA-CAPGEMINI (BE) - E-
ORDER 2018-23107 - LAURA FERNANDEZ - 
INTERFACE DESIGNER LEVEL 3 
GROW.R.3 - SLG.CMM.2018.23196 - CS 15200 - CC 
DI/7333 - EUROPEAN DYNAMICS (LU) - E-
ORDER 2018-23196 - VIRGILIU RATOI - 
APPLICATION ARCHITECT/DESIGNER LEVEL 2  
GROW.R.3 - SLG.CMM.2018.23522 - CS 15196 - CC 
DI/7335 - INNOVATIA-INTRASOFT(LU) - E-
ORDER 2018-23522 - PANAGIOTIS FOTIADIS - 
BUSINESS ANALYST LEVEL 3  
GROW.R.3 - SLG.CMM.2018.23657 - CS 15198 - CC 
DI/7335 - INNOVATIA-TRASYS (BE) - E-ORDER 
2018-23657 - MELHI TUZUNOGLU - ENTREPRISE 

60 

100 000.00 

1 087.30 

2 995.86 

1 402.32 

70 501.20 

22 044.47 

27 926.24 

45 917.20 

42 025.20 

40 462.20 

28 862.00 

30 653.15 

23 598.40 

30 653.15 

24 626.00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARCHITECT LEVEL 4  
GROW.R.3 - SLG.CMM.2018.25709 - CS 15577 - CC 
DI/7330 - EURORA-1-ARHS (LU) - E-ORDER 2018-
25709 - SWATHI CHANDRASHEKARAIAH - 
APPLICATION ARCHITECT/DESIGNER LEVEL 2 
GROW.R.3 - SLG.CMM.2018.28754 - CS 15580 - CC 
DI/7335 - INNOVATIA-ATOS (BE) - E-ORDER 
2018-28754 - IONUT TUDOR - BUSINESS 
ANALYST LEVEL 3  
GROW.R.3 - SLG.CMM.2018.29131 - CS 15582 - CC 
DI/7335 - INNOVATIA-FUJITSU(BE) - E-ORDER 
2018-29131 - TOM LARMINIER - ENTERPRISE 
ARCHITECT LEVEL 3  
GROW.R.3 - SLG.CMM.2018.29347 - CS 15593 - CC 
DI/7335 - INNOVATIA-TRASYS(BE) - E-ORDER 
2018-29347 - MICHAIL SAITAS - BUSINESS 
ANALYST LEVEL 5  
GROW.R.3 - SLG.CMM.2018.30880 - CS 15826 - CC 
DI/7331 - PANOPLYS-ATOS(BE) - E-ORDER 2018-
30880 - MICHAEL CASEY - APPLICATION 
ARCHITECT DESIGNER LEVEL 4  
GROW.R.3 - CS 939 - CC DI/7700 - XPE 
GROUP(BE) - E-ORDER 2018-36614 - JAN DE 
COCK - APPLICATION ARCHITECT LEVEL 5 
GROW.R.3 - E-ORDER 2018-36975 - CS 16100 - CC 
DI/7331 - REMO MORO - PANOPLYS-
TRASYS(BE) - APPLICATION 
ARCHITECT/DESIGNER LEVEL 3 
GROW.R.3 - SLG.CMM.2018.36982 - CS 16093 - CC 
DI/7335 - INNOVATIA-CAPGEMINI (BE) - E-
ORDER 2018-36982 - LAURA FERNANDEZ - 
INTERFACE DESIGNER LEVEL 3  
GROW.R.3 - SLG.CMM.2018.37023 - CS 16106 - CC 
DI/7335 - INNOVATIA-TRASYS (BE) - E-ORDER 
2018-37023 - MELHI TUZUNOGLU - ENTREPRISE 
ARCHITECT LEVEL 4 
GROW.R.3 - CS 16098 - CC DI/7330 - EURORA-1-
ARHS (LU) - E-ORDER 2018-37027 - MIHNEA 
ANDREI MAGHETI - APPLICATION 
ARCHITECT/DESIGNER LEVEL 3 
GROW.R.3 - SLG.CMM.2018.37163 - CS 16090 - CC 
DI/7331 - PANOPLYS-TRASYS (BE) - E-ORDER 
2018-37163 - ASHLEY COUPLAND - 
APPLICATION ARCHITECT/DESIGNER LEVEL 4 
GROW.R.3 - CS 16107 - CC DI/7330 - EURORA-1-
ORDINA (BE) - E-ORDER 2018-37191 - ARUNIMA 
VERMA - APPLICATION DEVELOPER - LEVEL 4  
GROW.R.3 - CS 16089 - CC DI/7331 - PANOPLYS-
ATOS(BE) - E-ORDER 2018-37222 - MICHAEL 
CASEY - APPLICATION ARCHITECT DESIGNER 
LEVEL 4 
GROW.R.3 - SLG.CMM.2018.37312 - CS 16091 - CC 
DI/7334 - FOUR-CE-UNISYSTEMS(BE) - E-ORDER 

61 

18 693.85 

16 719.90 

21 492.00 

20 231.10 

10 823.25 

63 841.50 

13 119.20 

11 146.60 

24 626.00 

11 750.20 

21 646.50 

8 078.40 

18 038.75 

17 709.40 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2018-37312 - OMAR EL YAHYAOUI - 
APPLICATION ARCHITECT/DESIGNER LEVEL 3 
GROW.R.3 - SLG.CMM.2018.37344 - CS 16096 - CC 
DI/7331 - PANOPLYS-INTRASOFT(LU) - E-
ORDER 2018-37344 - RICHARD HOULIHAN - 
APPLICATION ARCHITECT/DESIGNER LEVEL 5 
GROW.R.3 - CS 16097 - CC DI/7335 - INNOVATIA-
FUJITSU(BE) - E-ORDER 2018-37649 - TOM 
LARMINIER - ENTERPRISE ARCHITECT LEVEL 
3 
GROW.R.3 - CS 2392 - CC DI/7390 - SINCRONIT-
SERCO (BE) - E-ORDER 2018-37817 - JEAN-NOEL 
CLAES - WORKSTATION ADMINISTRATOR 
LEVEL 5 
GROW.R.3 - CS 16095 - CC DI/7335 - INNOVATIA-
FUJITSU (BE) - E-ORDER 2018-37870 - NINA 
GEORGIEVA - BA LEVEL 3 
GROW.R.3 - CS 16092 - CC DI/7337 - EURORA-2-
ORDINA(BE) - E-ORDER 2018-37884 - EZEKIEL 
FATUROTI - QUALITY CONSULTANT LEVEL 4 
GROW.R.3 - CS 16094 - CC DI/7335 - INNOVATIA-
INTRASOFT(LU) - E-ORDER 2018-37897 - 
PANAGIOTIS FOTIADIS - BUSINESS ANALYST 
LEVEL 3 
GROW.R.3 - CS 16105 - CC DI/7335 - INNOVATIA-
ATOS(BE) - E-ORDER 2018-38049 - IONUT 
TUDOR - BUSINESS ANALYST LEVEL 3 
GROW.R.3 - CS 1125 - CC DI/7700 - XPE 
GROUP(BE) - E-ORDER 2018-38277 - EWA OLOW 
- ENTERPRISE ARCHITECT LEVEL 5 - 
EUR 116 883.00  
GROW.R.3 - CS 1059 - CC DI/7701 - EURORA 
NOVA (LU) - E-ORDER 2018-39461 - ZOUHAIR 
ESSIKAL - PROJECT MANAGER LEVEL 5 
GROW.R.3 - CS 1566 - CC DI/7700 - XPE GROUP 
(BE) - E-ORDER 2018-39764 - MARTINE GUEBEL 
- PROJECT MANAGER - LEVEL 5 
GROW.R.3 - CS 1600 - CC DI/7700 - XPE GROUP 
(BE) - E-ORDER 2018-40320 - EZEKIEL 
FATUROTI - TECHNOLOGY EXPERT - LEVEL 4 
GROW.R.3 - SLG.CMM.2018.40656 - CS 1156 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2018-40656 - BRENDAN DOHERTY - 
APPLICATION ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2018.40866 - CS 1227 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2018-40866 - SWATHI CHANDRASHEKARAIAH - 
APPLICATION ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2018.41180 - CS 1208 - CC 
DI/7701 - EURORA NOVA (LU) - E-ORDER 2018-
41180 - MINHEA ANDREI MAGHETI - 
APPLICATION ARCHITECT LEVEL 4 

62 

24 803.80 

14 328.00 

18 926.80 

22 293.20 

18 010.80 

13 933.25 

16 719.90 

36 363.60 

22 754.13 

29 792.70 

58 528.80 

73 803.00 

72 608.40 

65 958.00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GROW.R.3 - SLG.CMM.2018.41342 - CS 1345 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2018-41342 - SORIN STEFANESCU - ENTERPRISE 
ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2018.42588 - CS 1213 - CC 
DI/7713 - TEIDE-EVERIS(BE) - E-ORDER 2018-
42588 - JOSE RAMOS - IS SUPPORT MANAGER 
LEVEL 4 
GROW.R.3 - SLG.CMM.2018.43038 - CS 1349 - CC 
DI/7713 - TEIDE-EVERIS(BE) - E-ORDER 2018-
43038 - JEAN-NOEL CLAES - SUPPORT 
MANAGER LEVEL 3 
GROW.R.3 - SLG.CMM.2018.43089 - CS 1347 - CC 
DI/7701 - EURORA NOVA (LU) - E-ORDER 2018-
43089 - PANAGIOTIS FOTIADIS - BUSINESS 
ANALYST LEVEL 5 
GROW.R.3 - CS 1522 - CC DI/7701 - EURORA 
NOVA (LU) - E-ORDER 2018-43288 - CHRISTIAN 
AIONESA - APPLICATION ARCHITECT LEVEL 4 

GROW.R.3 - CS 1157 - CC DI/7704 - 
EXXEEUB(BE) - E-ORDER 2018-43512 - NINA 
GEORGIEVA - BUSINESS ANALYST LEVEL 5 
GROW.R.3 - SLG.CMM.2018.44284 - CS 1516 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-44284 - REMO MORO - APPLICATION 
ARCHITECT LEVEL 4 
GROW.R.3 - SLG.CMM.2018.44477 - CS 1205 - CC 
DI/7701 - EURORA NOVA-AHRS(LU) - E-ORDER 
2018-44477 - VAN TAN NGUYEN - APPLICATION 
ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2018.44768 - CS 1663 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-44768 - WILLIAM PROCTER - QUALITY 
ASSURANCE MANAGER LEVEL 3 
GROW.R.3 - SLG.CMM.2018.44929 - CS 1346 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-44929 - TOM LARMINIER - ENTERPRISE 
ARCHITECT LEVEL 5 
GROW.R.3 - SLG.CMM.2018.45053 - CS 1226 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-45053 - ASHLEY COUPLAND - 
APPLICATION ARCHITECT LEVEL 5  
GROW.R.3 - SLG.CMM.2018.45501 - CS 1207 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-45501 - MICHAEL CASEY - APPLICATION 
ARCHITECT LEVEL 5 
GROW.R.3 - CS 1280 - CC DI/7704 - EXXEL4EUB-
TRASYS(BE) - E-ORDER 2018-45630 - LAURA 
FERNANDEZ Y GARCIA - UX UI SPECIALIST 
LEVEL 4  
GROW.R.3 - CS 1277 - CC DI/7704 - EXXEL4EUB-
TRASYS(BE) - E-ORDER 2018-45680 - OMAR EL 
YAHYAOUI - APPLICATION ARCHITECT LEVEL 

63 

9 266.19 

12 510.52 

13 872.60 

52 691.75 

11 212.86 

62 235.00 

68 929.00 

7 195.40 

5 247.50 

75 222.00 

67 699.80 

22 566.60 

57 123.00 

75 222.00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5  

GROW.R.3 - SLG.CMM.2018.45759 - CS 1817 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-45759 - TSVETAN YOLOV - APPLICATION 
ARCHITECT LEVEL 3 
GROW.R.3 - CS 1168 - CC DI/7704 - EXXEL4EUB-
TRASYS(BE) - E-ORDER 2018-45898 - RICHARD 
HOULIHAN - APPLICATION ARCHITECT LEVEL 
5 
GROW.R.3 - SLG.CMM.2018.47383 - CS 243 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2018-47383 - KUMAR PRASHANT - 
APPLICATION ARCHITECT LEVEL 3 
GROW.R.3 - SLG.CMM.2018.47603 - CS 1348 - CC 
DI/7702 - BORN4ITB-CRONOS(LU) - E-ORDER 
2018-47603 - ARUNIMA VERMA - APPLICATION 
DEVELOPER LEVEL 4 
GROW.R.3 - SLG.CMM.2018.47757 - CS 1281 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-47757 - ZBIGNIEW WASIK - TECHNOLOGY 
EXPERT LEVEL 5 
GROW.R.3 - SLG.CMM.2018.48301 - CS 1344 - CC 
DI/7704 - EXXEL4EUB-TRASYS(BE) - E-ORDER 
2018-48301 - IONUT TUDOR - ENTERPRISE 
ARCHITECT LEVEL 3  
GROW.R.3 - SLG.CMM.2018.50297 - CS 3268 - CC 
DI/7445 - LIGHTWAY-ARHS (LU) - E-ORDER 
2018-50297 - MELIH TUZUNOGLU - 
TECHNOLOGY EXPERT SENIOR 
Development of the future EUDAMED (the European 
medical devices database for the new Regulations on 
medical devices and in vitro diagnostic medical 
devices) 

3.7. Health information and knowledge system 
including support to the Scientific Committees set up 
in accordance with Commission Decision 
2008/721/EC 
Title 

C2 - 17030100 - SC 261 - ASSISTANCE TO 
SCIENTIFIC COMMITTEES AND HEALTH EU 
NEWSLETTER - ONLINE WRITER AND 
WEB/VISUAL DESIGNER -NOVACOMM 

4 
4. Facilitate access to better and safer healthcare for 
Union citizens 
4.1. Support the establishment of a system of European 
reference networks 

64 

63 208.00 

83 066.40 

55 831.50 

44 650.00 

11 075.52 

69 528.80 

33 834.68 

290 915.16 

2 452 600.00 

Amount committed 
in EUR 
250 000.00 

250 000.00 

Total 

Thematic priority: 

User reference 

Total 
Objectives 
Description of 
objectives 
Thematic priority 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
User reference 

Title 

B3 - 17030100 - SANTE/2017/B3/046 - 
ORGANISATION 4TH CONFERENCE ON ERN - 
21-22/11/2018 - BRUSSELS - TIPIK 
B3 - 17030100 - SANTE/201/B3/012 - REPORT ON 
EUROPEAN REFERENCE NETWORKS 
RESEARCH CAPABILITIES 
B3 - 17030100 - SANTE/2018/B3/027 - VIDEO CLIP 
PRODUCTION ERN 
B3 - 17030100 - CS SANTE/01 - PRODUCTION ET 
INSTALLATION BANNER FOR ERN 19-
21/11/2018 - CREASET - CHANGE BA 
ERN activities  

ERN and cross-border actions 

Total 
Cross-cutting actions related to all objectives (IT/dissemination) 
User reference 

Title 

SC 10531 - PS - PROJECT MANAGER FOR 
HEALTH - COMPL 
SC 116 - WEB MAINTENANCE DG SANTE 
WEBSITES 2018 
02 - VIDEO CLIP ON VACCINATION - 
SANTE/2018/02/013 - DEG 
SC 13798 - BK - PROJECT MANAGER FOR 
HEALTH SYSTEMS 
SC 13798 - BK - PROJECT MANAGER FOR 
HEALTH SYSTEMS 
SC 13798 - BK - PROJECT MANAGER FOR 
HEALTH SYSTEMS 
SC 2128 - RD - TECHNICAL TEAM 
COORDINATOR FOR EU MEDICINAL 
PRODUCTS – EMP 
SC 13791 - DB - APPLICATION ARCHITECT 
DESIGNER FOR EUROPEAN MEDICINAL 
PRODUCTS (EMP) 
SC 13802 - OM - DATABASE DEVELOPER FOR 
COLLABORATIVE PLATFORMS, INJURY 
DATABASE, AND ECHI  
SC 13802 - OM - DATABASE DEVELOPER FOR 
COLLABORATIVE PLATFORMS, INJURY 
DATABASE, AND ECHI  
SC 14774 - CG - PROJECT MANAGER FOR 
SHAREPOINT  
SC 14774 - CG - PROJECT MANAGER FOR 
SHAREPOINT  
SC 2200 - OA - SECURITY ASSISTANT FOR 
SANTE PROJECTS (FS - PH) 
SC 13796 - MF - APPLICATION ARCHITECT 
DESIGNER FOR FOOD FRAUD & EUROCET 

65 

Amount committed 
in EUR 
57 000.00 

15 000.00 

27 840.90 

3 051.92 

4 000 000.00 

127 000.00 

4 229 892.82 

Amount committed 
in EUR 
5 000.00 

13 185.00 

14 555.00 

19 394.00 

8 000.00 

50 000.00 

141 240.00 

52 179.60 

12 000.00 

48 252.50 

38 677.00 

15 852.00 

23 070.50 

52 000.00 

 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CODING STANDARDS 
SC 13796 - MF - APPLICATION ARCHITECT 
DESIGNER FOR FOOD FRAUD & EUROCET 
CODING STANDARDS 
SC 14014 - CF - PROJECT MANAGER FOR EU-
CEG, FSCAP & CLINICAL TRIALS 
SC 14014 - CF - PROJECT MANAGER FOR EU-
CEG, FSCAP & CLINICAL TRIALS 
SC 13800 - VL - INTERFACE DESIGNER FOR 
FOOD SYSTEMS, COLLABORATIVE 
PLATFORMS, EU-CEG & DYNA 
SC 13800 - VL - INTERFACE DESIGNER FOR 
FOOD SYSTEMS, COLLABORATIVE 
PLATFORMS, EU-CEG & DYNA 
SC 14760 - ADW - DATABASE DEVELOPER BXL 
FOR TRACES, ERADICATION & HEALTH 
PROJECTS 
SC 15017 - ACB - USER SUPPORT PERSON BXL 
FOR EU-CEG & FOOD SYSTEMS 
SC 13812 - SM - APPLICATION 
ARCHITECT/DESIGNER FOR E-HEALTH & 
FOOD SAFETY PROJECTS 
SC 10151 - DC -DESIS III - QUALITY 
CONSULTANT FOR EHDSI PUBLIC HEALTH 
AND FOOD SAFETY PROJECTS 
OF 5044 - LTAS TECHNOLOGIES WIST 
LINKEDIN SUBSCRIPTION LICENCEE FOR 
PUBLIC HEALTH DIRECTORATE  
SC 14749 - NT - WEB OPERATION MANAGER 
FOR QUALITY TEAM 
SC 14749 - NT - WEB OPERATION MANAGER 
FOR QUALITY TEAM 
SC 15646 - CT - SPECIAL USER APPLICATION 
SUPPORT AND TESTING 
SC 15646 - CT - SPECIAL USER APPLICATION 
SUPPORT AND TESTING 
SC 15655 - MC - DATABASE DEVELOPER FOR 
SHAREPOINT SERVICES 
SC 15655 - MC - DATABASE DEVELOPER FOR 
SHAREPOINT SERVICES 
SC 15655 - MC - DATABASE DEVELOPER FOR 
SHAREPOINT SERVICES 
SC 15656 - AC - APPLICATION DEVELOPER IN 
GRANGE FOR VARIOUS FOOD SAFETY AND 
HEALTH APPLICATIONS USING THE XML 
GATE 3 PLATFORM 
SC 15488 - PDG - WEB OPERATION MANAGER 
FOR TOBACCO 
SC 15645 - KK - BUSINESS INTELLIGENCE 
ANALYST CONSULTANCY 
02 - SANTE/2018/02/039 - IMAGINA - 
ANIMATIONS ON VACCINATION CONFIDENCE 
REPORT 

66 

15 852.00 

30 000.00 

20 000.00 

5 000.00 

10 000.00 

10 000.00 

16 292.80 

13 759.13 

26 500.00 

1 173.82 

10 000.00 

10 000.00 

5 000.00 

5 000.00 

5 000.00 

2 500.00 

2 500.00 

5 000.00 

31 804.80 

9 014.00 

14 898.95 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SC 16117 - AA - DATABASE DEVELOPER FOR 
HEALTH AND FOOD POLICY PROJECTS 
SC 239 - DG SANTE WEBSITES MANAGEMENT 
OF 5645 - LICENCE - VMWARE VSPHERE 6 
ENTERPRISE PLUS 
SC 235 - EXTENDED APPLICATION SUPPORT 
(XAS) FOR HEALTH AND FOOD POLICY 
PROJECTS – OCTOBER 2018 – SEPTEMBER 2019 
(CD) 
OF 5688 - ELA VMWARE 
SC 245 - DG SANTE NOVACOMM WEB VISUAL 
DESIGNERS 
02 - PO-2016-12-A2-77-SANTE - SOCIAL MEDIA 
BOOSTING DG SANTE 
SC 255 - WEB MAINTENANCE AND HEALTH 
CRAWLER 
02 - SANTE/2018/02/049 - IMAGINA - VIDEO 
‘STATE OF HEALTH IN THE EU’ 
C4 - 17030100 - SC 270 - JR PROJECT MANAGER 
AND JR ONLINE COMMUNITY MANAGER EU 
HEALTH POLICY FORUM AND EU HEALTH 
AWARD -NOVACOMM 
02 - SANTE/2018/02/053 - IMAGINA - UPDATE 
VIDEO ‘STATE OF HEALTH IN THE EU’ 
SC 1023 - MF - APPLICATION ARCHITECT (LUX) 
PH & FF PROJECTS 
SC 1025 - PS - APPLICATION ARCHITECT (LUX) 
PH & FF PROJECTS 
SC 1043 - DC - USER SUPPORT MANAGEMENT 
(SPM) 
SC 1499 - OM - APPLICATION ARCHITECT (LUX) 
FOR PUBLIC HEALTH PROJECTS 
SC 1499 - OM - APPLICATION ARCHITECT (LUX) 
FOR PUBLIC HEALTH PROJECTS 
SC 1499 - OM - APPLICATION ARCHITECT (LUX) 
FOR PUBLIC HEALTH PROJECTS 
SC 1499 - OM - APPLICATION ARCHITECT (LUX) 
FOR PUBLIC HEALTH PROJECTS 
SC 1499 - OM - APPLICATION ARCHITECT (LUX) 
FOR PUBLIC HEALTH PROJECTS 
SC 1492 - AA - APPLICATION ARCHITECT (LUX) 
PH AND F&F PROJECTS 
SC 1492 - AA - APPLICATION ARCHITECT (LUX) 
PH AND F&F PROJECTS 
SC 1492 - AA - APPLICATION ARCHITECT (LUX) 
PH AND F&F PROJECTS 
SC 1496 - PG - APPLICATION ARCHITECT (LUX) 
PH AND F&F PROJECTS 
SC 1496 - PG - APPLICATION ARCHITECT (LUX) 
PH AND F&F PROJECTS 
SC 1496 - PG - APPLICATION ARCHITECT (LUX) 
PH AND F&F PROJECTS 

67 

20 000.00 

176 400.00 
10 000.00 

73 902.40 

2 274.44 
56 250.00 

17 925.00 

3 302.00 

19 945.95 

186 500.00 

2 000.00 

76 482.70 

48 584.00 

11 447.25 

66 697.50 

30 000.00 

24 517.30 

9 678.00 

25 000.00 

65 951.00 

25 000.00 

15 000.00 

15 000.00 

75 482.70 

31 000.00 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
02 - SANTE/2018/02/055 - INDIEPICS - VIDEO 
AND TRAILERS ON ‘ANTIMICROBIAL 
RESISTANCE’ 
SC 1500 - MS - APPLICATION ARCHITECT (LUX) 
PH AND FOOD & FEED PROJECTS 
SC 1500 - MS - APPLICATION ARCHITECT (LUX) 
PH AND FOOD & FEED PROJECTS 
SC 1497 - RD - APPLICATION ARCHITECT FOR 
PH AND FF PROJECTS 
SC 1497 - RD - APPLICATION ARCHITECT FOR 
PH AND FF PROJECTS 
02 - SANTE/2018/02/065 - PURCHASE OF 
PROMOTIONAL MATERIAL FOR DG SANTE - 
MOD MT 
SC 1051 - VL - TECHNOLOGY EXPERT (LUX) 
FOR FOOD & HEALTH POLICY PROJECTS 
SC 1051 - VL - TECHNOLOGY EXPERT (LUX) 
FOR FOOD & HEALTH POLICY PROJECTS 
SC 1009 - OA - ICT SECURITY MANAGER FOR 
FOOD SAFETY AND HEALTH PROJECTS 
SC 1009 - OA - ICT SECURITY MANAGER FOR 
FOOD SAFETY AND HEALTH PROJECTS 
SC 1009 - OA - ICT SECURITY MANAGER FOR 
FOOD SAFETY AND HEALTH PROJECTS 
SC 1694 - AC - QUALITY ASSURANCE 
MANAGER FOR FOOD AND HEALTH PROJECTS 
SC 1176 - DC - TECHNOLOGY EXPERT QUALITY 
ASSURANCE HEALTH AND FOOD SAFETY 
SYSTEMS 
SC 1176 - DC - TECHNOLOGY EXPERT QUALITY 
ASSURANCE HEALTH AND FOOD SAFETY 
SYSTEMS 
SC 1176 - DC - TECHNOLOGY EXPERT QUALITY 
ASSURANCE HEALTH AND FOOD SAFETY 
SYSTEMS 
SC 2037 - DS - APPLICATION ARCHITECT FOR 
FOOD SAFETY AND HEALTH PROJECTS 
SC 1266 - JS - TECHNOLOGY EXPERT FOR 
EHDSI  
SC 1266 - JS - TECHNOLOGY EXPERT FOR 
EHDSI  
02 - SANTE/2018/12 - EVALUATION OF 
COMMUNICATION TOOLS DG SANTE 
B1 - 17.030100 - SANTE/2018/C1/062 - SERVICES 
FOR A WORKSHOP DURING THE 19TH 
INTERNATIONAL CONFERENCE ON 
INTEGRATED CARE.  
SANTE/2018/02/067 - ACHIEVEMENTS IN THE 
AREA OF HEALTH AND FOOD SAFETY 
CO-DEL DG SANTE- TRADUCTIONS 2018    
SC 1548 - JG - BUSINESS ANALYST FOR E-
HEALTH DEG - RECOMMITTED ON SI2.801057 
SC 1548 - JG - BUSINESS ANALYST FOR E-

68 

12 970.00 

120 951.00 

15 000.00 

20 000.00 

63 422.10 

3 745.56 

30 000.00 

20 000.00 

10 000.00 

7 833.33 

10 000.00 

25 000.00 

20 000.00 

48 552.75 

20 000.00 

25 000.00 

2 500.00 

11 211.97 

12 200.00 

14 398.00 

700.00 

65 185.81 
44 392.23 

17 347.47 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HEALTH DEG - RECOMMITTED ON SI2.801057 
CC07490, CS000097, 2018-17474, SOPRA STERIA 
BENELUX, MANAGED SERVICES PROVISION 
(MSP II),  
BASIC SERVICES - CORE SERVICES - 
STARTDATE: 01/06/2018 (UNTIL 31/10/2018) - 
MODE SERVICE - BASIC SERVICES CORE 
CC07590, CSS046, 2018-26985, ORACLE 
BELGIUM BVBA* 
ACQUISITION OF ORACLE LICENSES AND 
ASSOCIATED SERVICES, RNW ORACLE - CC 
07590, PERIOD: 19/08/2018 - 18/08/2019 S046 - 
LICENCES - ORACLE 
CC07460, CS000132, 2018-41321, DIMENSION 
DATA BELGIUM - OUT-TASKING OF 
ACTIVITIES FOR SYSTEMS AND 
INFRASTRUCTURE SERVICES (OASIS II) -
EXTENSION OF CS 105 - PREST - MODE 
SERVICE (OASIS): ARCHITECTURE 
CC, CSSC 259, 2018-43932, AUSY BELGIUM, 
COMM/A5 - NOVACOMM - PO/2016-20/A - 
DIGITAL COMMUNICATION SERVICES, 
PROJECT MANAGER SENIOR - SUPPORT_ WEB 
PRESENCE 
CC07490, CS000125, 2018-50345, SOPRA STERIA 
BENELUX, MANAGED SERVICES PROVISION 
(MSP II), SECURITY SERVICES - MODE SERVICE 
- SUPPORTING SERVICE DEVELOPMENT 
CC07610, CS484, 2018-54250, CANCOM ONLINE, 
PROVISION OF DATA CENTRE COMPUTE 
SOLUTIONS (DCCS) - LOT 1, A2S-26SFF-T-AM4 
HPE DL380 26SFF FC NO HBA T NICS, 5Y 
GUARANTEE - COMPUTE PLATFORMS - 
VIRTUALISATION HARDWARE PURCHASE 
CC, CS274, 2018-54336, AUSY BELGIUM, 
COMM/A5 - NOVACOMM - PO/2016-20/A - 
DIGITAL COMMUNICATION SERVICES, WEB 
DEVELOPER SENIOR - SUPPORT_ WEB 
PRESENCE 
CC07720, CS1003189, 2018-54930, BECHTLE 
BRUSSELS, 
SOFTWARE FOR INNOVATION, DIVERSITY 
AND EVOLUTION II (SIDE II) SERVICES 
LIFERAY - SUPPORT – IPCIS 
CC07610, CS569A, 2018-55667, CANCOM 
ONLINE, PROVISION OF DATA CENTRE 
COMPUTE SOLUTIONS (DCCS) - LOT 1 A2S-
26SFF-T-AM4 HPE DL380 26SFF FC NO HBA T 
NICS - CORPORATE INFRASTRUCTURE - 
VIRTUALIZATION PLATFORM - LEASING 
CC07720, CS1002926, 2018-53802, BECHTLE 
BRUSSELS SOFTWARE FOR INNOVATION, 
DIVERSITY AND EVOLUTION II (SIDE II) 

69 

35 400.00 

3 913.54 

450 968.21 

57 000.00 

11 658.00 

161 280.00 

4 000.00 

5 846.87 

32 390.79 

19 819.80 

 
 
 
 
 
 
 
 
 
 
 
 
LIFERAY SUBSCRIPTION PORTAL EE - GOLD 
(NON-PRODUCTION) 12 MONTHS DURATION: 
30/12/2018 - 29/12/2019 - LICENCES - CM TOOLS - 
LIFERAY 
CONFERENCE ‘THE WAY FORWARD FOR HTA 
COOPERATION’ - 9 JULY 2018 - BRUSSELS - DG 
SANTE - SCIC/2018/C1/2725619 - AMEX 
CONFERENCE ‘THE WAY FORWARD FOR HTA 
COOPERATION’ - 9 JULY 2018 - BRUSSELS - DG 
SANTE - SCIC/2018/C1/2821828 
CONFERENCE ‘THE WAY FORWARD FOR HTA 
COOPERATION’ - 9 JULY 2018 - BRUSSELS - DG 
SANTE - SCIC/2018/C1/3073687 
CONFERENCE ‘THE WAY FORWARD FOR HTA 
COOPERATION’ - 9 JULY 2018 - BRUSSELS - DG 
SANTE - SCIC/2018/C1/3251217 - OBJECTIF 
CONFERENCE ‘THE WAY FORWARD FOR HTA 
COOPERATION’ - 9 JULY 2018 - BRUSSELS - DG 
SANTE - SCIC/2018/C1/3609705 - E. VIDAL 
CONFERENCE ‘THE WAY FORWARD FOR HTA 
COOPERATION’ - 9 JULY 2018 - BRUSSELS - DG 
SANTE - COMMANDE 10346 - COMPASS 
ICT 

14 985.86 

685.70 

1 722.00 

367.00 

800.00 

14.977.48 

136 782.74 
3 404 049.55 
10 373 942.37 

Total 
SANTE TOTAL 
SERVICE 
CONTRACTS 

OTHER ACTIONS 

EUR 5 509 503.09 was committed for other actions in 2018. Other actions cover contributions paid by the 

EU  as  a  member  of  the  European  Observatory  on  Health  Systems  and  Policies  and  the  administrative 

agreements with the Commission’s JRC.  

This  also  includes  the  cost  of  the  cross-sub-delegations  with  Eurostat  for  morbidity  statistics  and  the 

European health interview surveys (EHIS), the medical device coordination group (MDCG) meetings, the 

VICH and  ICH international cooperation, and the special indemnities paid to experts for participating in 

meetings and for work on scientific opinions and advice on health systems. 

The table below provides more information on ‘other actions’. 

Financial instrument 
Objectives 
Description of objectives  3. Contribute to innovative, efficient and sustainable health 

Chafea other actions by objective 
3 

Thematic priority 

systems 
3.7. Foster a health information and knowledge system to 
contribute to evidence-based decision-making 

70 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
User reference 

Title 

20185101 

Total 

MEMBERSHIP CONTRIBUTION TO EUROPEAN 
OBSERVATORY ON HCS & POLICIES 

1-4 

Objectives 
Description of objectives  Related to all programme objectives 
Thematic priority 
User reference 

N/A (Expert evaluators) 
Title 

HP-PJ-2018 
HP-PJ-02-2018 
HP-JA-2018 
HP-SGA-2018 
HP-ERN-SGA-2018 
Total 
Chafea TOTAL 
OTHER ACTIONS 

Financial 
instrument 
Objectives 
Description of 
objectives 

Thematic priority 

User reference 

C1 - SI2.791956 - 
17030100 - AA No 
35088  

Total 

Evaluation call for proposals  
Evaluation call for proposals  
Quality assurance workshop JA 2018 
Evaluation OG/SGA 2018  
Evaluation ERN/SGA 2018  

SANTE other actions by objective 

1 

1. Promote health, prevent diseases and foster supportive 
environments for healthy lifestyles 
1.1. Support the exchange of evidence-based and good 
practices for addressing risk factors such as tobacco use and 
passive smoking, harmful use of alcohol, unhealthy dietary 
habits and physical inactivity 
Title 

JRC ON HQ-HIP, HEALTHCARE QUALITY, HEALTH 
INFORMATION AND PROMOTION.   

Thematic priority 

1.5. Implementation of Union legislation in the field of tobacco 
products  

User reference 
B2 - SI2.793649 - 
17.030100 - AA No 
35352  

Title 
JRC TECHNICAL SUPPORT TO THE IMPLEMENTATION 
OF THE TOBACCO PRODUCTS DIRECTIVE 

71 

Amount 
committed in 
EUR 

500 000.00 

500 000.00 

Amount 
committed in 
EUR 
15 304.00 
7 227.00 
8 968.00 
34 860.00 
31 300.00 
97 659.00 
597 659.00 

Amount 
committed in 
EUR 

2 000 000.00 

2 000 000.00 

Amount 
committed in 
EUR 
100 000.00 

 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Total 

Objectives 
Description of 
objectives 
Thematic priority 

User reference 

Technical and scientific support TPD: Article 4.4  

3 
3. Contribute to innovative, efficient and sustainable health 
systems 
3.4. Setting up a mechanism for pooling expertise at Union 
level 
Title 

B1 - 17.0301 - SPECIAL INDEMNITIES EXPERTS FROM 
EXPERT PANEL ON EFFECTIVE WAYS OF INVESTING 
IN HEALTH 
C2 - 17.0301 - SCIENTIFIC COMMITTEES TRAVEL AND 
INDEMNITIES FOR EXPERTS - COMPL 

3.6. Implementation of Union legislation in the field of medical 
devices, medical products and cross-border healthcare 
Title 

Total 
Thematic priority 

User reference 

E5=VICH MEETINGS - C(2017)8350 
E5=VICH MEETINGS - C(2017)8350 
F5 - SI2.775691 - 17.0301 - REIMBURSEMENT OF 
EXPERTS ON ACTIVE PHARMACEUTICAL 
INGREDIENTS: SYSTEM INSPECTIONS IN NON-EU 
COUNTRIES. 
2018 ICH MEETINGS 
B5 - SI2.778194 - 2018 - ICH MEETING - AMEX KOBE - 
DEG 
B5 - SI2.778194 - 2018 - ICH MEETING - AMEX 
CHARLOTTE -  
B5 - SI2.795300 - 2018 - ICH MEETING - AMEX TOKYO  
B5 - SI2.788574 - ICH MEMBERSHIP FEE FOR 2019 
F5 - 17.0301 - REIMBURSEMENT OF EXPERTS FOR 
JOINT ASSESSMENTS ON MEDICAL DEVICES 
B5 - SI2.774999 - JAP AUDIT PROGRAMME (JAP) ON 
GOOD MANUFACTURING PRACTICE (GMP) 
INSPECTIONS FOR MUTUAL RECOGNITION 
AGREEMENT ON GMP INSPECTIONS BETWEEN THE 
EU AND THE US AND OTHER STRATEGIC PARTNERS - 
COMPL 
GROW/D4 - ADMINISTRATIVE ARRANGEMENT WITH 
JRC - SUPPORT FOR THE ESTABLISHMENT OF 
SCIENTIFIC BODIES AND FOR NOMENCLATURE IN 
THE FIELD OF MEDICAL DEVICES 

60 000.00 
160 000.00 

Amount 
committed in 
EUR 
165 000.00 

370 000.00 

535 000.00 

Amount 
committed in 
EUR 
1 200.00 
6 200.00 
30 000.00 

80 000.00 
72 620.45 

135 379.64 

10 000.00 
240 000.00 
224 000.00 

80 000.00 

349 864.00 

1 229 264.09 

Total 
Thematic priority 

User reference 

3.7. Foster a health information and knowledge system, 
including support to the Scientific Committees set up in 
accordance with Commission Decision 2008/721/EC 
Title 

Amount 

72 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cross sub-delegation to Eurostat implemented through the 
direct award of grants for testing new modules/variables for 
future European Health Interview Survey (EHIS) waves 
Sub-delegation to Eurostat implemented through the direct 
award of grants for morbidity statistics 
Sub-delegation to Eurostat implemented through the direct 
award of grants for non-monetary healthcare statistics 

committed in 
EUR 

413 943.00 

527 575.00 

46 062.00 

987 580.00 
4 911 844.09 

Total 
SANTE TOTAL 
OTHER ACTIONS 

73 

 
 
 
 
 
 
 
 
 
DETAILED OVERVIEW OF THE REPORTING YEAR 2018 

Funding per thematic priority and financial instrument 

Objectives 

1 

1. Promote health, prevent diseases and foster supportive environments for healthy lifestyles  

Chafea 
projects 
grants by 
objective 

Chafea ERN 
actions 
SGAs under 
FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea 
joint 
actions by 
objective 

Chafea direct 
grant 
agreements 
by objective 

Chafea 
Presidency 
conferences 
by objective 

Chafea service 
contracts by 
objective 

SANTE service 
contracts by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

0.00 

0.00 

2 698 599.53 

0.00 

0.00 

100 000.00 

999 350.00 

0.00 

0.00 

2 000 000.00 

5 797 949.53 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

Description of 
objectives 

Third health 
programme 
thematic 
priorities 

1.1. Cost-
effective 
promotion and 
prevention 
measures in line, 
in particular, with 
the Union 
strategies on 
alcohol and 
nutrition 
1.2. Measures to 
complement the 
Member States’ 
action in reducing 
drug-related 
health damage, 
including 
information and 
prevention 

74 

 
 
 
 
 
 
 
 
 
 
 
 
 
1.3. Support 
effective 
responses to 
communicable 
diseases, such as 
HIV/AIDS, 
tuberculosis and 
hepatitis 

1.4. Support 
cooperation and 
networking in the 
Union to prevent 
and improve the 
response to 
chronic diseases 
including cancer, 
age-related 
diseases and 
neurodegenerativ
e diseases 
1.5. 
Implementation 
of Union 
legislation in the 
field of tobacco 
products 
1.6. Foster a 
health 
information and 
knowledge 
system to 
contribute to 
evidence-based 
decision-making 
Total 

0.00 

0.00 

640 708.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

640 708.00 

6 806 454.13 

0.00 

769 679.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

7 576 133.13 

0.00 

0.00 

0.00 

0.00 

720 000.00 

0.00 

841 630.00 

0.00 

0.00 

160 000.00 

1 721 630.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

6 806 454.13 

0.00 

4 108 986.53 

0.00 

720 000.00 

100 000.00 

1 840 980.00 

0.00 

0.00 

2 160 000.00 

15 736 420.66 

Objectives 

2 

75 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Description of 
objectives 
Third health 
programme thematic 
priorities 

2.1. Improve risk 
assessment and close 
gaps in risk 
assessment capacities 

2.2. Support capacity 
building against 
health threats in 
Member States 
Total 

2. Protect Union citizens from serious cross-border health threats 

Chafea 
projects 
grants by 
objective 

Chafea ERN 
actions SGAs 
under FPA 
by objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

0.00 

0.00 

0.00 

0.00 

Chafea 
direct grant 
agreements 
by 
objective 

0.00 

Chafea 
Presidency 
conferences by 
objective 

Chafea 
service 
contracts by 
objective 

SANTE service 
contracts by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

7 900 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

7 900 000.00 

0.00 

0.00 

0.00 

7 900 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

7 900 000.00 

Objectives 

3 

Description of 
objectives 
Third health 
programme 
thematic priorities 

3.1. Support 
voluntary cooperation 
between Member 
States on health 
technology 
assessment 
3.2. Promote the 
voluntary uptake of 
health innovation and 
e-Health  
3.3. Support the 
sustainability of the 
health workforce  

3. Contribute to innovative, efficient and sustainable health systems 

Chafea 
projects grants 
by objective 

Chafea ERN 
actions 
SGAs under 
FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea direct 
grant 
agreements by 
objective 

Chafea 
Presidency 
conferences 
by objective 

Chafea service 
contracts by 
objective 

SANTE 
service 
contracts by 
objective 

Chafea 
other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

750 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

750 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

76 

 
 
 
 
 
 
 
 
 
 
 
 
 
299 994.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

37 400.00  

0.00 

535 000.00 

872 394.00  

0.00 

0.00 

250 000.00 

0.00 

0.00 

0.00 

531 000.00 

2 452 600.00 

0.00 

1 229 264.09 

4 462 864.09 

0.00 

0.00 

0.00 

0.00 

600 000.00 

0.00 

0.00 

250 000.00 

500 000.00 

987 580.00 

2 337 580.00 

299 994.00 

0.00 

250 000.00 

0.00 

1 350 000.00  

0.00 

531 000.00 

2 740 000.00 

500 000.00 

2 751 844.09 

8 422 838.09 

3.4. Provide expertise 
and share good 
practices to assist 
Member States 
undertaking health 
system reforms 
3.6. Implementation 
of Union legislation 
in the field of medical 
devices, medicinal 
products and cross-
border healthcare 

3.7. Foster a health 
information and 
knowledge system to 
contribute to 
evidence-based 
decision-making 
Total 

Objectives 

4 

4. Facilitate access to better and safer healthcare for Union citizens 

Chafea 
projects 
grants by 
objective 

Chafea ERN 
actions SGAs 
under FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

Chafea direct 
grant 
agreements by 
objective 

Chafea 
Presidency 
conferences 
by objective 

Chafea 
Call for 
tenders by 
objective 

SANTE calls 
for tenders by 
objective 

Chafea 
other 
actions by 
objective 

Total 

SANTE 
other actions 
by objective 

749 884.35 

13 691 043.13 

0.00 

0.00 

0.00 

0.00 

0.00 

4 229 892.82 

0.00 

0.00 

18 670 820.30 

Description of 
objectives 
Third health 
programme thematic 
priorities 

4.1. Support the 
establishment of a 
system of European 
reference networks  

77 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2. Coordinated 
action at Union level 
to help patients 
affected by rare 
diseases in an effective 
way 
4.3. Strengthen 
cooperation on patient 
safety and quality of 
healthcare 
4.4. Improve the 
prudent use of 
antimicrobial agents 
and reduce the 
practices that increase 
antimicrobial 
resistance 

4.5. Implementation of 
Union legislation in 
the fields of human 
tissues and cells, 
blood, human organs, 
medical devices, 
medicinal products 
and patients’ rights in 
cross-border 
healthcare 
Total 

Related to all 
objectives 

0.00 

0.00 

1 281 251.00 

0.00 

3 239 462.53 

0.00 

0.00 

0.00 

0.00 

0.00 

4 520 713.53 

0.00 

0.00 

0.00 

0.00 

450 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

450 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

66 000.00 

0.00 

0.00 

0.00 

0.00 

66 000.00 

0.00 

0.00 

247 721.00 

0.00 

1 500 000.00 

0.00 

0.00 

0.00 

0.00 

0.00 

1 747 721.00 

749 884.35 

13 691 043.13 

1 528 972.00 

0.00 

5 189 462.53  

66 000.00 

0.00 

4 229 892.82 

0.00 

0.00 

25 455 254.83 

Other actions or expenditure 

IT / dissemination / prizes ( cross-cutting, other actions related to all objectives)  

Third health 
programme thematic 
priorities 

Chafea projects 
grants by 
objective 

Chafea ERN 
actions SGAs 
under FPA by 
objective 

Chafea 
operating 
grants by 
objective 

Chafea joint 
actions by 
objective 

SANTE calls 
for tenders by 
objective 

Chafea other 
actions by 
objective 

SANTE other 
actions by 
objective 

Total 

Chafea 
direct 
grant 
agreements 
by 
objective 

Chafea 
Presidency 
conferences 
by 
objective 

Chafea Call 
for tenders 
by 
objective 

78 

 
 
 
 
 
 
 
 
 
 
 
 
 
3.1. Prizes 

4.1.5. Dissemination

Expert evaluators  

Horizontal/ 
ICT/dissemination 

Total 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

0.00 

60 000.00 

0.00 

0.00 

97 659.00 

0.00 

0.00 

0.00 

60 000.00 

246 032.85 

97 659.00 

0.00 

0.00 

0.00 

246 032.85 

0.00 

0.00 

0.00 

0.00 

3 404 049.55 

0.00 

0.00 

3 404 049.55 

0.00 

246 032.85 

3 464 049.55 

97 659.00 

0.00 

3 807 741.40 

TOTAL ACTIONS COMMITTED BY CHAFEA UNDER 2018 AWP  

TOTAL ACTIONS COMMITTED BY DG SANTE UNDER 2018 AWP  

TOTAL COMMITTED                     

45 976 468.52 

15 345 786.46 

61 322 254.98 

79